Page last updated: 2024-11-11

rifaximin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6436173
CHEMBL ID1617
CHEBI ID75246
SCHEMBL ID124066
MeSH IDM0126046

Synonyms (88)

Synonym
AC-19112
AB01209738-03
redactiv
alpha-0817185
xifaxan
rifacol
normix
flonorm
l-105
lormyx
lumenax
spiraxin
xifaxan (tn)
rifaximin (jan/usan/inn)
D02554
l 105
c43h51n3o11
brn 3584528
fatroximin
4-deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4-c)rifamycin sv
(2s,16z,18e,20s,21s,22r,23r,24r,25s,26s,27s,28e)-5,6,21,23,25 pentahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca(1,11,13)trienimino)benzofuro(4,5-e)pyrido(1,2-a)benzimidazole-1,15(2h)-dione, 25-acetate
rifaximinum [latin]
rifamixin
l 105sv
ritacol
2,7-(epoxypentadeca(1,11,13)trienimino)benzofuro(4,5-e)pyrido(1,2-a)benzimidazole-1,15(2h)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, (2s-(2r*,16z,18e,20r*,21r*,22s*,23s*,24s*,25r*,26s*,27r*,28e))-
l 105 (ansamacrolide antibiotic)
rifamycin l 105sv
rifaxidin
DB01220
rifamycin l 105
4-deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4c)rifamycin
chebi:75246 ,
xifaxsan
nsc-758957
CHEMBL1617
dtxsid7045998 ,
rifaximine
rifaximinum
rifaximina
bdbm50347620
AKOS015963053
rifaximinun
(2s,16z,18e,20s,21s,22r,23r,24r,25s,26r,27s,28e)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-1,15-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)furo[2'',3'':7',8']naphtho[1',2':4,5]imidazo[1,2-a]pyridin-25-yl acetate
rifaxin
nsc 758957
l36o5t016n ,
2,7-(epoxy(1,11,13)pentadecatrienoimino)furo(2'',3'':7',8')naphth(1',2':4,5)imidazo(1,2-a)pyridine-1,15(2h)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, ( 2s,16z,18e,20s,21s,22r,23r,24r,25s,26r,27s,28e)-
rifaximin [usan:inn:ban]
unii-l36o5t016n
rifaximin [mart.]
rifaximin [ep impurity]
rifaximin [usan]
rifaximin [jan]
rifaximin [who-dd]
rifaximin [vandf]
rifaximin [orange book]
2,7-(epoxypentadeca(1,11,13)trienimino)benzofuro(4,5-e)pyrido(1,2-a)benzimidazole-1,15(2h)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, (2s,16z,18e,20s,21s,22r,23r,24r,25s,26r,27s,28e)-
rifaximin [mi]
(2s,16z,18e,20s,21s,22r,23r,24r,25s,26r,27s,28e)-25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca(1,11,13)trienimino)benzofuro(4,5-e)pyrido(1,2-a)benzimidazole-1,15(2h)-dione
rifaximin [inn]
rifaximin [ep monograph]
S1790
CCG-221129
NZCRJKRKKOLAOJ-XRCRFVBUSA-N
AB01209738-01
SCHEMBL124066
Q-201671
rifaximin, antibiotic for culture media use only
(2s,16z,18e,20s,21s,22r,23r,24r,25s,26r,27s,28e)-25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2h)-dione
AB01209738_04
mfcd00864973
HMS3715B19
5-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)furo[2'',3'':7',8']naphtho[1',2':4,5]imidazo[1,2-a]pyridin-2
5-yl acetate
(2s,16z,18e,20s,21s,22r,23r,24r,25s,26r,27s,28e)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-1,1
Q416073
HB2568
rifaximin 1000 microg/ml in acetonitrile
l/105
[(7s,9e,11s,12r,13s,14r,15r,16r,17s,18s,19e,21z)-2,15,17,36-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6,23-dioxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.14,7.05,35.026,34.027,32]heptatriaconta-1(35),2,4,9,19,21,25(36),26(34),28,30,32-un
gtpl12012
rifaximin (ep monograph)
a07aa11
rifaximin (mart.)
rifaximinum (latin)
rifaximin (ep impurity)
d06ax11

Research Excerpts

Overview

Rifaximin is a poorly absorbed semisynthetic antibiotic derivative of rifampin licensed for use in the treatment of traveler's diarrhea.

ExcerptReferenceRelevance
"Rifaximin is an oral antibiotic indicated for treatment of traveler's diarrhea. "( Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.
Bourgeois, AL; Carpenter, C; Durbin, A; Haake, R; McKenzie, R; Taylor, DN, 2008
)
2.08
"Rifaximin is a poorly absorbed semisynthetic antibiotic derivative of rifampin licensed for use in the treatment of traveler's diarrhea. "( Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
Brown, EL; Dupont, HL; Jiang, ZD; Xu, Y; Xue, Q, 2010
)
2.07

Effects

ExcerptReferenceRelevance
"Rifaximin has been evaluated in adults for treatment of bacterial enteritis and has a good record for safety and efficacy, but it has not been evaluated extensively in children with gastroenteritis."( Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli.
Chen, J; Cleary, TG; Gonzales, E; Ochoa, TJ; Walker, CM, 2007
)
2.5

Treatment

ExcerptReferenceRelevance
"Rifaximin-treated samples containing bile acids inhibited the expression of ETEC beta-galactosidase at a higher magnitude than samples that did not contain bile acids."( Bile acids improve the antimicrobial effect of rifaximin.
Ajami, N; Darkoh, C; Dial, EJ; DuPont, HL; Jiang, ZD; Lichtenberger, LM, 2010
)
1.34

Bioavailability

Rifaximin is a poorly absorbed semisynthetic antibiotic derivative of rifampin licensed for use in the treatment of traveler's diarrhea.

ExcerptReferenceRelevance
"Rifaximin, a poorly absorbed rifamycin derivative, is a promising alternative for the treatment of Clostridium difficile infections."( Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.
Galang, MA; Gerding, DN; Hecht, DW; Johnson, S; O'Connor, JR; Sambol, SP; Vedantam, G, 2008
)
2.16
"Rifaximin is a poorly absorbed semisynthetic antibiotic derivative of rifampin licensed for use in the treatment of traveler's diarrhea."( Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
Brown, EL; Dupont, HL; Jiang, ZD; Xu, Y; Xue, Q, 2010
)
2.07
" The purpose of the present study was to evaluate the antimicrobial effect and bioavailability of rifaximin in aqueous solution in the presence and absence of physiologic concentrations of bile acids."( Bile acids improve the antimicrobial effect of rifaximin.
Ajami, N; Darkoh, C; Dial, EJ; DuPont, HL; Jiang, ZD; Lichtenberger, LM, 2010
)
0.83

Dosage Studied

ExcerptRelevanceReference
" The study provides data showing that bile acids solubilize rifaximin on a dose-response basis, increasing the drug's bioavailability and antimicrobial effect."( Bile acids improve the antimicrobial effect of rifaximin.
Ajami, N; Darkoh, C; Dial, EJ; DuPont, HL; Jiang, ZD; Lichtenberger, LM, 2010
)
0.86
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
gastrointestinal drugA drug used for its effects on the gastrointestinal system, e.g. controlling gastric acidity, regulating gastrointestinal motility and water flow, and improving digestion.
orphan drugAny drug that has been developed specifically for treatment of a rare medical condition, the condition itself being known as an orphan disease.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
rifamycins
acetate esterAny carboxylic ester where the carboxylic acid component is acetic acid.
lactamCyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
organic heterohexacyclic compound
macrocycleA cyclic compound containing nine or more atoms as part of the cyclic system.
semisynthetic derivativeAny organic molecular entity derived from a natural product by partial chemical synthesis.
cyclic ketalA ketal in the molecule of which the ketal carbon and one or both oxygen atoms thereon are members of a ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)65.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)30.20000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)42.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)15.40002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)EC50 (µMol)9.12000.00203.519610.0000AID1071341; AID1215086; AID1215087; AID1255423; AID606749
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (52)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
negative regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
steroid metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of gene expressionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic catabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic transportNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (32)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
nucleoplasmNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intermediate filament cytoskeletonNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (317)

Assay IDTitleYearJournalArticle
AID535442Antimicrobial activity against Lactobacillus acidophilus by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535216Antimicrobial activity against Clostridium symbiosum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535212Antimicrobial activity against Clostridium sporogenes by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID1513920Apparent permeability of the compound after 5 hrs by PAMPA2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Alkyl-guanidine Compounds as Potent Broad-Spectrum Antibacterial Agents: Chemical Library Extension and Biological Characterization.
AID535458Antimicrobial activity against Propionibacterium acnes by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID521281Tmax in Shigella flexneri challenged human at 200 mg/kg, po administered every 8 hrs for three days measured after third dose2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.
AID531310Drug level in diarrhea patient feces at 400 mg, po every 12 hrs for 3 days2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.
AID534728Antimicrobial activity against Bacteroides nordii by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID508224Inhibition of enteroaggregative Escherichia coli 042 adherence to human Hep2 cells pretreated at 64 ug/ml for 24 hrs by adherence assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID534720Antimicrobial activity against Parabacteroides goldsteinii by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535434Antimicrobial activity against Eubacterium limosum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID546936Antibacterial activity against Salmonella enterica serovar Choleraesuis by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546933Antibacterial activity against Salmonella enterica serovar Paratyphi by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID534734Antimicrobial activity against Bilophila wadsworthia by Wadsworth agar dilution method in presence of 1% pyruvic acid2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID519416Antibacterial activity against Clostridium difficile VPI 10463 infected in golden syrian hamster assessed as survival of the mouse at 50 mg/kg/day administered 24 hrs after infection for 5 days measured after 7 days2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.
AID535246Antimicrobial activity against Colinsella aerofaciens by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535248Antimicrobial activity against Coprobacillus cateniformis by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID519419Antibacterial activity against Clostridium difficile VPI 10463 infected in golden syrian hamster assessed as body weight gain at 100 mg/kg/day for 5 days relative to initial body weight2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.
AID535182Antimicrobial activity against Clostridium disporicum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535472Antimicrobial activity against Peptoniphilus harei by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534998Antimicrobial activity against Clostridium cocleatum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID1879497Antibacterial activity against Helicobacter pylori ATCC 7003922022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens.
AID534948Antimicrobial activity against Fusobacterium sp. by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534964Antimicrobial activity against Prevotella intermedia by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535238Antimicrobial activity against Bifidobacterium longum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID576690Inhibition of RNA synthesis in Escherichia coli H10407 assessed as inhibition of beta-galactosidase expression relative to control2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Bile acids improve the antimicrobial effect of rifaximin.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID534930Antimicrobial activity against Desulfovibrio desulfuricans by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID534946Antimicrobial activity against Fusobacterium varium by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535190Antimicrobial activity against Clostridium lactatifermentans by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID508222Inhibition of enteroaggregative Escherichia coli 042 adherence to human Hep2 cells pretreated at 32 ug/ml for 24 hrs by adherence assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID535206Antimicrobial activity against Clostridium sordellii by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID546963Antibacterial activity against Yersinia pseudotuberculosis by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID508247Effect on cytokine level in human Hep2 cells assessed as IL-15 level pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID546969Antibacterial activity against Aeromonas caviae by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID535464Antimicrobial activity against Anaerococcus prevotii by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID546975Antibacterial activity against Aeromonas veronii by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID521280Cmax in Shigella flexneri challenged human at 200 mg/kg, po administered every 8 hrs for three days measured after last dose2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.
AID535436Antimicrobial activity against Eubacterium rectale by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID535470Antimicrobial activity against Peptoniphilus asaccharolyticus by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID519415Antibacterial activity against Clostridium difficile VPI 10463 infected in golden syrian hamster assessed as survival of the mouse at 100 mg/kg/day administered 24 hrs after infection for 5 days measured after 7 days2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.
AID547194Antibacterial activity against Campylobacter coli by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID535448Antimicrobial activity against Lactobacillus jensenii by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535432Antimicrobial activity against Eubacterium cylindroides by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535228Antimicrobial activity against Bifidobacterium adolescentis by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535478Antimicrobial activity against Ruminococcus flavefaciens by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID546960Antibacterial activity against Yersinia enterocolitica by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID508229Inhibition of Shigella sonnei adherence to human HeLa cells pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID535196Antimicrobial activity against Clostridium paraputrificum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535184Antimicrobial activity against Clostridium fallax by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535230Antimicrobial activity against Bifidobacterium bifidum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID546966Antibacterial activity against Aeromonas hydrophila by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID508236Effect on cytokine level in human Hep2 cells assessed as RANTES level pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID342194Effect on phage-mediated lysis of shiga toxin producing Escherichia coli non-O157 assessed as amount of free shiga toxin per well after 5 hrs by RT-PCR2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli.
AID1173607Apparent permeability of the compound at pH 10.0 after 5 hrs by PAMPA2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Synthesis of linear and cyclic guazatine derivatives endowed with antibacterial activity.
AID534956Antimicrobial activity against Porphyromonas uenonis by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535456Antimicrobial activity against Lactobacillus sp. by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID535484Antimicrobial activity against Ruminococcus luti by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534715Antimicrobial activity against Bacteroides fragilis by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534958Antimicrobial activity against Prevotella bivia by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID606969Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in human PXR expressing transgenic C57/BL6 mouse assessed as decrease in evidence of mucosal hemorrhage damage at 10 mg/kg, po qd administered 3 days before TNBS challenge meas2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID535486Antimicrobial activity against Ruminococcus obeum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID341089Antimicrobial activity against Clostridium difficile clinical isolates by agar dilution method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
AID508234Effect on cytokine level in human Hep2 cells assessed as MIP5 level pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID535194Antimicrobial activity against Clostridium nexile by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID547185Antibacterial activity against Vibrio vulnificus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID576691Inhibition of RNA synthesis in Escherichia coli H10407 assessed as inhibition of beta-galactosidase expression at 8 ug/ml in presence of 4 mM bile acid2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Bile acids improve the antimicrobial effect of rifaximin.
AID521419AUC (0 to last) in Shigella flexneri challenged human at 200 mg/kg, po administered every 8 hrs for three days measured after third dose2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.
AID534984Antimicrobial activity against Clostridium aminobutyricum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID534943Antimicrobial activity against Fusobacterium mortiferum by Wadsworth agar dilution method in presence of beta-lactamase inhibitor Sulbactam2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID508243Effect on cytokine level in human Hep2 cells assessed as IL-4 level pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID535234Antimicrobial activity against Bifidobacterium dentium by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID519413Antibacterial activity against Clostridium difficile VPI 10463 infected in golden syrian hamster assessed as body weight loss at 50 mg/kg/day for 5 days measured after 7 days relative to initial body weight2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.
AID535430Antimicrobial activity against Eubacterium callanderi by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID576687Antimicrobial activity against Escherichia coli H10407 assessed as decrease in cell density at 16 ug/ml after 4 hrs in presence of 4 mM glycocholic acid2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Bile acids improve the antimicrobial effect of rifaximin.
AID535444Antimicrobial activity against Lactobacillus catenaformis by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535236Antimicrobial activity against Bifidobacterium infantis by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534950Antimicrobial activity against Porphyromonas sp. by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID508239Effect on cytokine level in human Hep2 cells assessed as TNFRI level pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID535242Antimicrobial activity against Bifidobacterium pseudolongum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID546942Antibacterial activity against Salmonella enterica serovar Virchow by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546924Antibacterial activity against Salmonella enterica serovar Typhimurium by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID534996Antimicrobial activity against Clostridium cadaveris by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535200Antimicrobial activity against Clostridium rectum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID508227Inhibition of enteroaggregative Escherichia coli 042 adherence to human HCT-8 cells pretreated at 64 ug/ml for 24 hrs by adherence assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID535480Antimicrobial activity against Ruminococcus gnavus by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID576682Antimicrobial activity against Escherichia coli H10407 assessed as decrease in cell density at 16 ug/ml after 4 hrs in presence of 4 mM human bile acid2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Bile acids improve the antimicrobial effect of rifaximin.
AID508233Effect on cytokine level in human Hep2 cells assessed as MIP4 level pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID535482Antimicrobial activity against Ruminococcus lactaris by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535488Antimicrobial activity against Ruminococcus productus by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534954Antimicrobial activity against Porphyromonas somerae by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534934Antimicrobial activity against Desulfovibrio piger by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535476Antimicrobial activity against Peptostreptococcus micros by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID1215096Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID342203Effect on phage-mediated lysis of shiga toxin producing Escherichia coli having lytic growth pattern assessed as amount of free shiga toxin per well after 5 hrs by RT-PCR2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli.
AID534714Antimicrobial activity against Parabacteroides distasonis by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID519421Antibacterial activity against Clostridium difficile VPI 10463 infected in golden syrian hamster assessed as survival of the mouse at 25 mg/kg/day administered 24 hrs after infection for 5 days measured after 28 days2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.
AID508226Inhibition of enteroaggregative Escherichia coli 042 adherence to human A549 cells pretreated at 64 ug/ml for 24 hrs by adherence assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID1071343Transactivation of human full-length PXR transfected in human HepG2 cells co-transfected with RXR at 10 uM after 18 hrs by luciferase reporter gene assay2014European journal of medicinal chemistry, Feb-12, Volume: 73Insights on pregnane-X-receptor modulation. Natural and semisynthetic steroids from Theonella marine sponges.
AID534960Antimicrobial activity against Prevotella corporis by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID1153244Agonist activity at human PXR transfected in human HepG2 cells co-transfected with pSG5-RXR/pCMV-beta-galactosidase/p(CYP3A4)-TK-Luc at 10 uM after 18 hrs by luciferase reporter gene assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Bazedoxifene-scaffold-based mimetics of solomonsterols A and B as novel pregnane X receptor antagonists.
AID535468Antimicrobial activity against Finegoldia magna by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534994Antimicrobial activity against Clostridium butyricum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534724Antimicrobial activity against Bacteroides thetaiotaomicron by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535460Antimicrobial activity against Propionibacterium avidum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534944Antimicrobial activity against Fusobacterium necrophorum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID508223Inhibition of Bacillus anthracis adherence to human A549 cells pretreated at 64 ug/ml for 24 hrs by adherence assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID535202Antimicrobial activity against Clostridium scindens by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID534730Antimicrobial activity against Bacteroides stercoris by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535490Antimicrobial activity against Ruminococcus torques by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535204Antimicrobial activity against Clostridium septicum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535198Antimicrobial activity against Clostridium ramosum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535474Antimicrobial activity against Peptostreptococcus anaerobius by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534990Antimicrobial activity against Clostridium bifermentans by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID547173Antibacterial activity against Vibrio cholerae by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID606913Inhibition of NF-kappaB p65 DNA binding activity in LPS-stimulated human THP1 cells at 10 uM after 3 hrs by electrophoretic mobility shift assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID606964Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in human PXR expressing transgenic C57/BL6 mouse assessed as decrease in occurrence of diarrhea at 10 mg/kg, po qd administered 3 days before TNBS challenge measured after 7 da2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID535188Antimicrobial activity against Clostridium hastiforme by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534974Antimicrobial activity against Clostridium hathewayi by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535220Antimicrobial activity against Actinomyces meyeri by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535428Antimicrobial activity against Eubacterium biforme by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535224Antimicrobial activity against Actinomyces viscosus by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534722Antimicrobial activity against Bacteroides ovatus by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535186Antimicrobial activity against Clostridium glycolicum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535232Antimicrobial activity against Bifidobacterium breve by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534980Antimicrobial activity against Clostridium perfringens by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID508241Effect on cytokine level in human Hep2 cells assessed as VCAM-1 level pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID342212Effect on phage-mediated lysis of shiga toxin producing diarrhea-associated Escherichia coli isolates assessed as amount of free shiga toxin per well2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli.
AID534938Antimicrobial activity against Desulfovibrio sp. by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID576694Decrease in protein expression in Escherichia coli H10407 at 16 ug/ml after 4 hrs2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Bile acids improve the antimicrobial effect of rifaximin.
AID606971Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in human PXR expressing transgenic C57/BL6 mouse assessed as decrease in cellular infiltrate in colon at 10 mg/kg, po qd administered 3 days before TNBS challenge measured afte2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID547191Antibacterial activity against Campylobacter jejuni by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID534966Antimicrobial activity against Prevotella loescheii by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID534982Antimicrobial activity against Clostridium acetobutylicum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534978Antimicrobial activity against Clostridium orbiscindens by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535218Antimicrobial activity against Clostridium tertium by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534976Antimicrobial activity against Clostridium innocuum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID546972Antibacterial activity against Aeromonas sobria by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546921Antibacterial activity against Escherichia coli by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID534952Antimicrobial activity against Porphyromonas asaccharolyticus by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID342211Effect on phage-mediated lysis of shiga toxin producing HUS-associated Escherichia coli isolates assessed as amount of free shiga toxin per well2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli.
AID535446Antimicrobial activity against Lactobacillus fermentum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID547182Antibacterial activity against Vibrio fluvialis by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547188Antibacterial activity against Vibrio sp. by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID535426Antimicrobial activity against Eubacterium alactolyticum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID508238Effect on cytokine level in human Hep2 cells assessed as IFN-gamma level pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID546945Antibacterial activity against Salmonella enterica serovar Heidelberg by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID534986Antimicrobial activity against Clostridium bartlettii by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535440Antimicrobial activity against Holdemania filiformis by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID546957Antibacterial activity against Shigella dysenteriae by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID519420Antibacterial activity against Clostridium difficile VPI 10463 infected in golden syrian hamster assessed as survival of the mouse at 50 mg/kg/day administered 24 hrs after infection for 5 days measured after 28 days2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.
AID1542208Antimicrobial activity against MLSB-resistant Staphylococcus aureus incubated for 18 hrs by serial microdilution method2019European journal of medicinal chemistry, Apr-01, Volume: 167Synthesis, docking and antibacterial studies of more potent amine and hydrazone rifamycin congeners than rifampicin.
AID508221Inhibition of enteroaggregative Escherichia coli 042 adherence to human Hep2 cells pretreated by adherence assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID1255425Up regulation of full length PXR expression in human HepG2 cells at 10 uM after 18 hrs by quantitative real-time PCR analysis2015European journal of medicinal chemistry, Oct-20, Volume: 103Diethylstilbestrol-scaffold-based pregnane X receptor modulators.
AID535210Antimicrobial activity against Clostridium spiroforme by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535462Antimicrobial activity against Propionibacterium propionicum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID606975Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in human PXR expressing transgenic C57/BL6 mouse assessed as decrease in TNF-alpha protein level in colon at 10 mg/kg, po qd after 5 days by ELISA2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID535250Antimicrobial activity against Eggerthella lenta by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID521420AUC (0 to last) in Shigella flexneri challenged human at 200 mg/kg, po administered every 8 hrs for three days measured after last dose2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.
AID535240Antimicrobial activity against Bifidobacterium pseudocatenulatum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID576695Bacteriostatic activity against Escherichia coli H10407 at 8 ug/ml in presence of bile acid relative to absence of bile acid2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Bile acids improve the antimicrobial effect of rifaximin.
AID535450Antimicrobial activity against Lactobacillus plantarum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534968Antimicrobial activity against Prevotella melaninogenica by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID508244Effect on cytokine level in human Hep2 cells assessed as IL-6 level pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID546951Antibacterial activity against Shigella flexneri by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID535244Antimicrobial activity against Catenibacterium mitsuokai by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID535454Antimicrobial activity against Lactobacillus rhamnosus by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID576696Bacteriostatic activity against Escherichia coli H10407 at 16 ug/ml in presence of bile acid relative to absence of bile acid2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Bile acids improve the antimicrobial effect of rifaximin.
AID534988Antimicrobial activity against Clostridium beijerinckii by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID576692Inhibition of RNA synthesis in Escherichia coli H10407 assessed as inhibition of beta-galactosidase expression at 16 ug/ml in presence of 4nM bile acid2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Bile acids improve the antimicrobial effect of rifaximin.
AID547176Antibacterial activity against Vibrio parahaemolyticus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID535438Antimicrobial activity against Eubacterium saburreum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID606967Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in human PXR expressing transgenic C57/BL6 mouse assessed as decrease in edema of colon at 10 mg/kg, po qd administered 3 days before TNBS challenge measured after 7 days2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID535208Antimicrobial activity against Clostridium sp. by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534718Antimicrobial activity against Parabacteroides merdae by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID508225Inhibition of enteroaggregative Escherichia coli 042 adherence to human HeLa cells pretreated at 64 ug/ml for 24 hrs by adherence assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID508235Effect on cytokine level in human Hep2 cells assessed as MMP3 level pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID546930Antibacterial activity against Salmonella enterica serovar Typhi by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID534936Antimicrobial activity against Desulfovibrio vulgaris by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID576688Antimicrobial activity against Escherichia coli H10407 assessed as decrease in cell density at 16 ug/ml after 4 hrs in presence of 4 mM taurocholic acid2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Bile acids improve the antimicrobial effect of rifaximin.
AID519418Antibacterial activity against Clostridium difficile VPI 10463 infected in golden syrian hamster assessed as survival of the mouse at 100 mg/kg/day administered 24 hrs after infection for 5 days measured after 28 days2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.
AID606973Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in human PXR expressing transgenic C57/BL6 mouse assessed as decrease in appearance of epithelial erosions in colon at 10 mg/kg, po qd administered 3 days before TNBS challenge2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID534992Antimicrobial activity against Clostridium bolteae by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1879495Antibacterial activity against Staphylococcus aureus ATCC 292132022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens.
AID535214Antimicrobial activity against Clostridium subterminale by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID554046Transactivation of PXR in human HepG2 cells assessed as induction of beta-galactosidase activity at 10 uM by luciferase reporter gene assay2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
Solomonsterols A and B from Theonella swinhoei. The first example of C-24 and C-23 sulfated sterols from a marine source endowed with a PXR agonistic activity.
AID369459Inhibition of Staphylococcus epidermidis biofilm formation assessed as reduction of >2 log 10 bacterial count in biofilm after 24 hrs2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm.
AID547170Antibacterial activity against Plesiomonas shigelloides by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547179Antibacterial activity against Vibrio alginolyticus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID534970Antimicrobial activity against Clostridium clostridioforme by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID534932Antimicrobial activity against Desulfovibrio fairfieldensis by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID576684Antimicrobial activity against Escherichia coli H10407 assessed as decrease in cell density at 16 ug/ml after 4 hrs in presence of 4 mM cholic acid2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Bile acids improve the antimicrobial effect of rifaximin.
AID534962Antimicrobial activity against Prevotella disiens by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID508246Effect on cytokine level in human Hep2 cells assessed as IL-12 (p40) level pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID534972Antimicrobial activity against Clostridium difficile by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID342193Effect on phage-mediated lysis of shiga toxin producing Escherichia coli O157 assessed as amount of free shiga toxin per well after 5 hrs by RT-PCR2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli.
AID546948Antibacterial activity against Shigella sonnei by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID535226Antimicrobial activity against Atopobium minutum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID342206Effect on phage-mediated lysis of shiga toxin producing Escherichia coli O111:NM TW08607 assessed as amount of free shiga toxin per well after 5 hrs by RT-PCR2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli.
AID369451Antimicrobial activity against Staphylococcus epidermidis2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm.
AID535192Antimicrobial activity against Clostridium leptum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID508248Effect on cytokine level in human Hep2 cells assessed as absence of MIP5 pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID508228Inhibition of Bacillus anthracis internalization to human A549 cells pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID546927Antibacterial activity against Salmonella enterica serovar Enteritidis by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID535466Antimicrobial activity against Anaerococcus tetradius by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID521424Drug level in healthy human urine at 400 mg single dose2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.
AID534726Antimicrobial activity against Bacteroides caccae by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID1542206Antimicrobial activity against methicillin-resistant Staphylococcus aureus incubated for 18 hrs by serial microdilution method2019European journal of medicinal chemistry, Apr-01, Volume: 167Synthesis, docking and antibacterial studies of more potent amine and hydrazone rifamycin congeners than rifampicin.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1215089Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID546939Antibacterial activity against Salmonella enterica serovar Newport by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID606976Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in human PXR expressing transgenic C57/BL6 mouse assessed as decrease in INF-gamma protein level in colon at 10 mg/kg, po qd after 5 days2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID534940Antimicrobial activity against Fusobacterium nucleatum by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID521418Tmax in Shigella flexneri challenged human at 200 mg/kg, po administered every 8 hrs for three days measured after last dose2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.
AID535222Antimicrobial activity against Actinomyces odontolyticus by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID534732Antimicrobial activity against Bacteroides uniformis by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID546954Antibacterial activity against Shigella boydii by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID576683Antimicrobial activity against Escherichia coli H10407 assessed as decrease in cell density at 16 ug/ml after 4 hrs in presence of 4 mM pooled synthetic bile acid2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Bile acids improve the antimicrobial effect of rifaximin.
AID1542210Antimicrobial activity against Staphylococcus epidermidis ATCC 49134 incubated for 18 hrs by serial microdilution method2019European journal of medicinal chemistry, Apr-01, Volume: 167Synthesis, docking and antibacterial studies of more potent amine and hydrazone rifamycin congeners than rifampicin.
AID535452Antimicrobial activity against Lactobacillus reuteri by Wadsworth agar dilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID508237Effect on cytokine level in human Hep2 cells assessed as TGF-beta level pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID1542207Antimicrobial activity against Staphylococcus aureus ATCC 6538 incubated for 18 hrs by serial microdilution method2019European journal of medicinal chemistry, Apr-01, Volume: 167Synthesis, docking and antibacterial studies of more potent amine and hydrazone rifamycin congeners than rifampicin.
AID1173609Apparent permeability of the compound assessed as membrane retention at pH 10.0 after 5 hrs by PAMPA2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Synthesis of linear and cyclic guazatine derivatives endowed with antibacterial activity.
AID519410Antibacterial activity against Clostridium difficile VPI 10463 infected in golden syrian hamster assessed as survival of the mouse at 50 mg/kg/day for 5 days measured after 7 days2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.
AID531309Antimicrobial activity against Clostridium difficile clinical isolate obtained from patient after completion of two courses of drug treatment2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.
AID605694Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in human PXR expressing transgenic C57/BL6 mouse assessed as increase in IL-10 protein level in colon at 10 mg/kg, po qd after 5 days by ELISA2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID606970Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in human PXR expressing transgenic C57/BL6 mouse assessed as decrease in microscopic colon damage at 10 mg/kg, po qd administered 3 days before TNBS challenge measured after 7 2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID606966Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in human PXR expressing transgenic C57/BL6 mouse assessed as decrease in presence of indurations in colon at 10 mg/kg, po qd administered 3 days before TNBS challenge measured 2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID369457Inhibition of Staphylococcus epidermidis biofilm formation assessed as log 10 reduction of bacterial count in biofilm at 0.025 ug/ml per well after 24 hrs2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm.
AID342205Effect on phage-mediated lysis of shiga toxin producing Escherichia coli O103:NM TW07697 assessed as amount of free shiga toxin per well after 5 hrs by RT-PCR2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli.
AID519414Antibacterial activity against Clostridium difficile VPI 10463 infected in golden syrian hamster assessed as body weight loss at 25 mg/kg/day for 5 days measured after 7 days relative to initial body weight2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.
AID606974Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in human PXR expressing transgenic C57/BL6 mouse assessed as decrease in colonic myeloperoxidase activity at 10 mg/kg, po qd after 5 days using trimethylbenzidine as substrate 2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID605693Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in human PXR expressing transgenic C57/BL6 mouse assessed as decrease in TGF-beta1 protein level in colon at 10 mg/kg, po qd after 5 days2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID508232Effect on cytokine level in human Hep2 cells assessed as GM-CSF level pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID508230Inhibition of Shigella sonnei internalization to human HeLa cells pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID606965Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in human PXR expressing transgenic C57/BL6 mouse assessed as decrease in weight loss at 10 mg/kg, po qd administered 3 days before TNBS challenge measured after 7 days2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID1071341Agonist activity at human full-length PXR transfected in human HepG2 cells co-transfected with pSG5-RXR assessed as induction of transactivation by dual-luciferase reporter gene assay2014European journal of medicinal chemistry, Feb-12, Volume: 73Insights on pregnane-X-receptor modulation. Natural and semisynthetic steroids from Theonella marine sponges.
AID606978Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in human PXR expressing transgenic C57/BL6 mouse assessed as decrease in MIP-1alpha protein level in colon at 10 mg/kg, po qd after 5 days2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1215093Activation of rat PXR expressed in human HepG2 cells up to 46 uM after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID576689Antimicrobial activity against Escherichia coli H10407 assessed as decrease in cell density at 16 ug/ml after 4 hrs in presence of 4 mM lithocholic acid2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Bile acids improve the antimicrobial effect of rifaximin.
AID369452Ratio of MBC for Staphylococcus epidermidis to MIC for Staphylococcus epidermidis2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm.
AID1173606Apparent permeability of the compound at pH 7.4 after 5 hrs by PAMPA2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Synthesis of linear and cyclic guazatine derivatives endowed with antibacterial activity.
AID1879496Antibacterial activity against Clostridioides difficile ATCC 96892022Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID576686Antimicrobial activity against Escherichia coli H10407 assessed as decrease in cell density at 16 ug/ml after 4 hrs in presence of 4 mM chenodeoxycholic acid2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Bile acids improve the antimicrobial effect of rifaximin.
AID342204Effect on phage-mediated lysis of shiga toxin producing Escherichia coli without lytic growth pattern assessed as amount of free shiga toxin per well after 5 hrs by RT-PCR2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli.
AID1542209Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 incubated for 18 hrs by serial microdilution method2019European journal of medicinal chemistry, Apr-01, Volume: 167Synthesis, docking and antibacterial studies of more potent amine and hydrazone rifamycin congeners than rifampicin.
AID519409Antibacterial activity against Clostridium difficile VPI 10463 infected in golden syrian hamster assessed as survival of the mouse at 100 mg/kg/day for 5 days measured after 7 days2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID606968Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in human PXR expressing transgenic C57/BL6 mouse assessed as decrease in thickness of colon at 10 mg/kg, po qd administered 3 days before TNBS challenge measured after 7 days2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID342196Induction of bacteriolysis against shiga toxin producing Escherichia coli O26:H11 1370 at 0.049 to 50 ug/ml after 5 hrs by spectrophotometry2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli.
AID535492Drug level in stool of patient with traveler's diarrhea at 800 mg, po administered daily for 3 days2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
AID369453Inhibition of Staphylococcus epidermidis RNA polymerase mediated transcription2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm.
AID606972Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in human PXR expressing transgenic C57/BL6 mouse assessed as decrease in appearance of submucosal edema in colon at 10 mg/kg, po qd administered 3 days before TNBS challenge me2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID521422Oral bioavailability in human at 200 mg three times a day for 3 days2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.
AID576681Antimicrobial activity against Escherichia coli H10407 assessed as decrease in cell density at 16 ug/ml after 4 hrs2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Bile acids improve the antimicrobial effect of rifaximin.
AID606977Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in human PXR expressing transgenic C57/BL6 mouse assessed as decrease in IL-12p70 protein level in colon at 10 mg/kg, po qd after 5 days2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID508242Effect on cytokine level in human Hep2 cells assessed as VEGF level pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID519412Antibacterial activity against Clostridium difficile VPI 10463 infected in golden syrian hamster assessed as body weight loss at 100 mg/kg/day for 5 days measured after 7 days relative to initial body weight2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.
AID576693Inhibition of RNA synthesis in Escherichia coli H10407 assessed as inhibition of beta-galactosidase expression at 32 ug/ml in presence of 4 mM bile acid2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Bile acids improve the antimicrobial effect of rifaximin.
AID508231Inhibition of enteroaggregative Escherichia coli 042 adherence to human Hep2 cells using cell supernatants from pretreated at 64 ug/ml for 24 hrs by adherence assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1542211Antimicrobial activity against Enterococcus faecalis ATCC 29212 incubated for 18 hrs by serial microdilution method2019European journal of medicinal chemistry, Apr-01, Volume: 167Synthesis, docking and antibacterial studies of more potent amine and hydrazone rifamycin congeners than rifampicin.
AID521421Cmax in Shigella flexneri challenged human at 200 mg/kg, po administered every 8 hrs for three days measured after third dose2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.
AID342192Effect on phage-mediated lysis of shiga toxin producing Escherichia coli assessed as amount of free shiga toxin per well after 5 hrs by RT-PCR2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli.
AID605695Antiinflammatory activity against trinitrobenzenesulfonic acid-induced colitis in human PXR expressing transgenic C57/BL6 mouse assessed as induction of CYP3A11 mRNA expression in colon at 10 mg/kg, po qd after 5 days by quantitative RT-PCR2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID1173608Apparent permeability of the compound assessed as membrane retention at pH 7.4 after 5 hrs by PAMPA2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Synthesis of linear and cyclic guazatine derivatives endowed with antibacterial activity.
AID508240Effect on cytokine level in human Hep2 cells assessed as TNFR2 level pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID508245Effect on cytokine level in human Hep2 cells assessed as IL-8 level pretreated at 64 ug/ml for 24 hrs2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
AID1255423Transactivation of full length human PXR transfected in human HepG2 cells after 18 hrs by luciferase reporter assay relative to rifaximin2015European journal of medicinal chemistry, Oct-20, Volume: 103Diethylstilbestrol-scaffold-based pregnane X receptor modulators.
AID519411Antibacterial activity against Clostridium difficile VPI 10463 infected in golden syrian hamster assessed as survival of the mouse at 10 mg/kg/day for 5 days measured after 7 days2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID576680Antimicrobial activity against Escherichia coli H10407 assessed as growth inhibition at 16 ug/ml2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Bile acids improve the antimicrobial effect of rifaximin.
AID606749Transactivation of human PXR expressed in HepG2 cells after 18 hrs by luciferase reporter gene assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID342199Effect on phage-mediated lysis of shiga toxin producing Escherichia coli assessed as detectable extracellular free phage after 5 hrs by RT-PCR2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID521423Drug level in healthy human feces at 400 mg single dose2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.
AID576685Antimicrobial activity against Escherichia coli H10407 assessed as decrease in cell density at 16 ug/ml after 4 hrs in presence of 4 mM deoxycholic acid2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Bile acids improve the antimicrobial effect of rifaximin.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1215087Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID645568Agonist activity at PXR expressed in human HepG2 cells assessed as transactivation at 10 uM after 48 hrs by luciferase reporter gene assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei.
AID1542212Antimicrobial activity against Escherichia coli ATCC 25922 incubated for 18 hrs by serial microdilution method2019European journal of medicinal chemistry, Apr-01, Volume: 167Synthesis, docking and antibacterial studies of more potent amine and hydrazone rifamycin congeners than rifampicin.
AID1215086Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (30.77)29.6817
2010's16 (61.54)24.3611
2020's2 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 114.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index114.12 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index205.01 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (114.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.70%)5.53%
Reviews1 (3.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (92.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (168)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Progressive Renal Failure [NCT00748904]Phase 40 participants (Actual)Interventional2008-06-30Withdrawn
A Double-Blind, Randomized, Controlled Trial of Rifaximin Compared to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) [NCT00269399]Phase 3237 participants (Actual)Interventional2005-12-31Completed
A Randomized, Open-Label, Phase 2a Comparator Study to Assess the Pharmacodynamics, Safety and Pharmacokinetics of Oral Administration MNK6106 (L-Ornithine Phenylacetate) Versus Rifaximin in Subjects With Hepatic Cirrhosis and a History of Prior Episodes [NCT03712280]Phase 250 participants (Actual)Interventional2018-12-01Completed
Rifaximin Improves Insulin Resistance in Metabolic Syndrome and Reduces Insulin Requirement in Type 2 Diabetes [NCT03758144]80 participants (Anticipated)Interventional2018-11-01Recruiting
Randomized Control Trial Comparing Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer [NCT01345175]Phase 370 participants (Actual)Interventional2011-04-26Completed
Safety and Efficacy of Rifaximin Delayed Release 400 mg Tablets in Patients With Moderate-to-severe Papulopustular Rosacea and Positive Lactulose Breath Test. A Multicenter Double-blind, Placebo-controlled Randomized Clinical Trial [NCT03864978]Phase 2236 participants (Anticipated)Interventional2018-06-22Recruiting
Rifaximin and Misoprostol Combination Therapy for Healing of Small Bowel Ulcers in Aspirin Users With Small Bowel Bleeding: A Double Blind Randomized Trial [NCT03962283]Phase 2/Phase 378 participants (Anticipated)Interventional2019-08-02Recruiting
Multicenter Double Blind Randomized Clinical Trial Assessing the Benefit of Adherent Invasive E. Coli Eradication in Adult Ileal and Ileo-colonic Crohn Disease [NCT02620007]Phase 224 participants (Actual)Interventional2015-12-31Terminated(stopped due to insufficient recruitment)
Rifaximin Treatment of Papulopustular Rosacea: Double- Blinded, Placebo-Controlled, Crossover Study [NCT01359228]Phase 20 participants (Actual)Interventional2013-04-30Withdrawn
Evaluating the Therapeutic Efficacy of Rifaximin in Patients With Diabetic Gastroparesis Using Bloating as the Primary Endpoint. [NCT04254549]Phase 240 participants (Anticipated)Interventional2019-06-14Recruiting
A Phase II Study of Rifaximin (Xifaxan) for Patients With Sickle Cell Disease (SCD) [NCT03719729]Phase 220 participants (Anticipated)Interventional2018-08-22Recruiting
A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center, Therapeutic Equivalence Study to Compare Rifaximin 200 mg Tablets (Sandoz GmbH) to Xifaxan® 200 mg Tablets (Salix Pharmaceuticals, Inc.) and Placebo in Patients With Travelers' [NCT02920242]Phase 328 participants (Actual)Interventional2016-12-15Terminated(stopped due to Terminated due to low enrollment)
Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis [NCT05408910]Phase 2/Phase 3100 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Rifaximin Predicts the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial [NCT02074280]Phase 4250 participants (Anticipated)Interventional2013-10-31Recruiting
Effects of Rifaximin Treatment in Patients With Acute Alcoholic Hepatitis: A Comparative Pilot Study [NCT02116556]Phase 229 participants (Actual)Interventional2013-04-30Enrolling by invitation
Rifaximin Associated With Classic Triple Therapy (Inhibitor of Proton Pump, Amoxicillin and Clarithromycin) for the Eradication of Helicobacter Pylori Infection [NCT03124199]Phase 340 participants (Actual)Interventional2014-02-28Completed
The Effect of Rifaximin on Portal Vein Thrombosis in Cirrhotic Patients [NCT03631147]96 participants (Anticipated)Interventional2018-09-03Not yet recruiting
Effect of Gut Decontamination Using Rifaximin in the Patients With Severe Alcoholic Hepatitis [NCT02485106]Phase 3170 participants (Anticipated)Interventional2015-07-31Not yet recruiting
Rifaximin Reduces the Complications of Decompensated Cirrhosis [NCT02190357]Phase 4200 participants (Anticipated)Interventional2014-08-31Recruiting
Effectiveness of Rifaximin on Preventing Postoperative Endoscopic Recurrence in Crohn's Disease Patients Without Risk Factor for Recurrence: A Multicenter Randomized Controlled Trial [NCT03185624]Phase 380 participants (Anticipated)Interventional2017-07-25Not yet recruiting
Randomized Control Trial of Rifaximin and Norfloxacin in Primary and Secondary Prophylaxis of Spontaneous Bacterial Peritonitis(SBP) in Cirrhotic Patients [NCT03695705]Phase 3142 participants (Actual)Interventional2016-01-01Completed
Rifaximin-treatment of Collagenous Colitis: [NCT03658993]Phase 350 participants (Anticipated)Interventional2018-11-01Not yet recruiting
Pilot, Single Center, Open, Trial of Rifaximin in Probable Alzheimer's Disease [NCT03856359]Phase 210 participants (Actual)Interventional2019-04-09Completed
Evaluation of Immunohistological Pattern in Patients With Uncomplicated Symptomatic Diverticular Disease and Correlation Between Intraluminal Bacterial Flora and Phlogosis [NCT02068482]Phase 461 participants (Actual)Interventional2010-11-30Completed
Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis [NCT02120196]Phase 3100 participants (Anticipated)Interventional2014-01-31Recruiting
Efficacy and Safety of Fecal Microbiota Transplantation for Irritable Bowel Syndrome [NCT03613545]Phase 2/Phase 3120 participants (Anticipated)Interventional2018-08-10Recruiting
Comparison of Three Different Schemes:Lactulose, L-ornithine L-aspartate, or Rifaximin, Versus Placebo, as Primary Prophylaxis of the Development of Hepatic Encephalopathy After Acute Variceal Bleeding in Cirrhotic Patients [NCT02158182]Phase 488 participants (Actual)Interventional2014-07-31Completed
Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial [NCT01218568]120 participants (Actual)Interventional2010-10-31Completed
Efficacy of a Probiotic Formula in Reducing Small Intestinal Bacterial Overgrowth (SIBO) in Patients With Irritable Bowel Syndrome (IBS) [NCT04316806]8 participants (Actual)Interventional2020-11-20Terminated(stopped due to Principal Investigator changed his job)
Effect of Rifaximin Therapy on Brain Activation in Patients With Minimal Hepatic Encephalopathy Using Functional MR, MR Spectroscopy,Diffusion Tensor Imaging Microbiome and Metabolome: a Prospective Trial [NCT01069133]Phase 1/Phase 220 participants (Actual)Interventional2010-02-28Completed
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE) [NCT03515044]Phase 271 participants (Actual)Interventional2018-09-13Completed
A Randomized Open Labelled Placebo Controlled Trial to Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism [NCT02265484]50 participants (Actual)Interventional2013-11-30Completed
A Randomized, Prospective, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of Rifaximin for the Treatment of Moderate to Severe Crohn's Disease [NCT00603616]Phase 236 participants (Actual)Interventional2008-11-30Completed
Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis: a Multi-center Randomized Prospective Study [NCT05863364]150 participants (Anticipated)Interventional2023-08-18Recruiting
Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome [NCT03557788]Phase 433 participants (Actual)Interventional2018-05-07Completed
A Randomized Single-Blind Controlled Trial Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation [NCT05453916]Phase 1/Phase 284 participants (Anticipated)Interventional2022-07-01Recruiting
Rifaximin Prophylaxis Against Recurrence of Spontaneous Bacterial Peritonitis and Occurrence of Hepatorenal Syndrome in Decompensated Cirrhotic Egyptian Patients [NCT05621005]Phase 2104 participants (Actual)Interventional2019-03-01Completed
Efficacy and Safety Evaluation of Rifaximin Combined Fecal Microbiota Transplantation in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea [NCT02651740]Phase 2/Phase 310 participants (Anticipated)Interventional2016-04-30Recruiting
Treating Bacterial Overgrowth in Parkinson's Disease [NCT02470780]Phase 2/Phase 324 participants (Actual)Interventional2015-12-31Completed
Rifaximin for Preventing Acute Graft Versus Host Disease [NCT00967096]Phase 120 participants (Actual)Interventional2007-04-30Completed
Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With Diarrhoea-predominant Irritable Bowel syndrome-a Multicentre Controlled Study [NCT04074421]Phase 4240 participants (Anticipated)Interventional2020-05-10Recruiting
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome [NCT00724126]Phase 3637 participants (Actual)Interventional2008-07-31Completed
Primary Prophylaxis for Spontaneous Bacterial Peritonitis in Decompensated Chronic Liver Disease With Small Bowel Bacterial Overgrowth: A Randomised Trial [NCT04775329]Phase 2/Phase 32 participants (Actual)Interventional2020-11-01Terminated(stopped due to Slow recruitment and study closure)
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy [NCT00298038]Phase 3299 participants (Actual)Interventional2005-12-19Completed
Single Daily Dose Rifaximin vs. Standard Thrice Daily Dosing for the 3-Day Treatment of Travelers' Diarrhea [NCT00875875]Phase 40 participants (Actual)Interventional2009-06-30Withdrawn(stopped due to No study population in Mexico (H1N1). Study withdrawn from IRB consideration.)
Effects of Rifaximin, by Modulation of the Gut Microbiota, on Markers of Systemic Inflammation in Patients With Common Variable Immunodeficiency - An Exploratory Open-label Randomized Controlled Trial [NCT01946906]Phase 440 participants (Actual)Interventional2013-10-31Completed
A Phase IIa, Multicenter, Double Blind, Placebo Controlled, Randomized Clinical Trial to Assess Safety, Efficacy and Pharmacokinetics of Rifaximin Delayed-Release (Rifaximin-EIR) in Patients With Moderate-to-severe Papulopustular Rosacea [NCT05150587]Phase 2216 participants (Actual)Interventional2021-10-05Completed
A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg Daily or 550 mg Twice Daily) for Chemoprophylaxis Against Travelers' Diarrhea (TD) Among Active Duty Deployed U.S. and British Military Person [NCT02498301]449 participants (Actual)Interventional2015-11-10Completed
RiFL: Rifaximin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)? [NCT01355575]Phase 415 participants (Actual)Interventional2011-05-31Terminated(stopped due to Primary endpoint data review concluded no further patients required.)
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure [NCT02086825]Phase 30 participants (Actual)Interventional2015-10-31Withdrawn
Probiotic E.Coli Nissle 1917 Comparing to Lactulose and Rifaximin in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy [NCT04787276]42 participants (Actual)Interventional2017-01-10Completed
Open-Label, Randomized, Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers [NCT05159427]Phase 140 participants (Anticipated)Interventional2022-03-15Recruiting
A Phase II, Multicentre, Double-blind, Randomised, Placebo-controlled Study of Rifaximin Delayed Release 400 mg Tablet: Clinical Efficacy and Safety in the Prevention of Post-operative Endoscopic Crohn's Disease Recurrence [NCT03537157]Phase 243 participants (Actual)Interventional2017-11-16Terminated(stopped due to The decision to prematurely close the trial recruitment period was taken due to the difficulties in the recruitment of patients. This decision has not been triggered by any unexpected safety signals identified during the study conduction.)
Phase II Trial of Rifaximin in Patients With Early Stage HER2 Positive Breast Cancer With Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy [NCT04249622]Phase 220 participants (Actual)Interventional2020-09-18Active, not recruiting
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease [NCT05098028]Phase 244 participants (Actual)Interventional2022-03-22Completed
Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex [NCT00956150]Phase 1210 participants (Anticipated)Interventional2009-04-30Recruiting
Prospective, Randomised, Placebo Controlled, Double Blind Monocenter Trial for the Prophylactic Treatment of Diarrhoea With Rifaximin for Travellers to South- and Southeast-Asia [NCT00979056]Phase 3258 participants (Actual)Interventional2009-10-31Completed
The Efficacy and Safety of Rifaximin In The Treatment of HBV Associated Acute-on-Chronic Liver Failure Patients With Mild to Moderate Hepatic Encephalopathy [NCT05786859]Early Phase 1124 participants (Anticipated)Interventional2023-03-09Recruiting
A Randomized, Triple-blind, Placebo-controlled Study on the Effect of Rifaximin on Psychobiological Functions in Healthy Men [NCT05587036]Phase 2/Phase 360 participants (Anticipated)Interventional2023-02-02Recruiting
Evaluation of the Efficacy and Safety of Rifaximin in Combination With N-acetylcysteine (NAC) in Adult Patients With Irritable Bowel Syndrome With Diarrhea [NCT04557215]Phase 1/Phase 245 participants (Actual)Interventional2020-11-13Completed
Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis [NCT04043897]Phase 210 participants (Anticipated)Interventional2018-06-29Recruiting
RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial [NCT00364689]Phase 313 participants (Actual)Interventional2006-08-31Terminated(stopped due to Difficult to recruit participants)
A Multi-Center, Open-Label Trial to Evaluate the Long-Term Safety and Tolerability of Rifaximin 550 mg BID in Subjects With a History of Hepatic Encephalopathy [NCT00686920]Phase 3322 participants (Actual)Interventional2007-03-07Completed
GutHeart: Targeting Gut Microbiota to Treat Heart Failure [NCT02637167]Phase 2150 participants (Anticipated)Interventional2016-03-11Recruiting
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome [NCT00731679]Phase 3623 participants (Actual)Interventional2008-07-31Completed
Autologous Hematopoietic Stem Cell Transplant for Crohn's Disease [NCT04154735]Phase 20 participants (Actual)Interventional2019-11-30Withdrawn(stopped due to Discontinued by Investigator)
Diarrhea-Predominant Irritable Bowel Syndrome in Persian Gulf Veterans [NCT00680836]54 participants (Actual)Interventional2007-10-31Completed
Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy [NCT04161053]Phase 360 participants (Anticipated)Interventional2018-11-01Recruiting
Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Single Center, Randomized, Placebo Controlled, Double-blind Phase 2 Trial [NCT04118699]Phase 212 participants (Anticipated)Interventional2019-12-25Active, not recruiting
Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Metastatic Lung Cancer [NCT05502913]Phase 280 participants (Anticipated)Interventional2023-09-01Recruiting
Effect of Fecal Microbiota Transfer on Progression of Parkinson Disease [NCT05204641]Phase 1/Phase 260 participants (Actual)Interventional2021-11-01Active, not recruiting
An Exploratory Assessment of Small Bowel Transit Time and Small Bowel Bacterial Overgrowth Using the SmartPill Capsule [NCT00577772]17 participants (Actual)Interventional2007-11-30Terminated(stopped due to Enrollment Goal Not Met)
[NCT02931123]Phase 1/Phase 258 participants (Anticipated)Interventional2015-11-30Recruiting
Multi-dimensional Clinical and Pathophysiological Profiles of Patients With Functional Dyspepsia and Effect of Gut Microbiota Manipulation Using Rifaximin for Its Treatment: A Randomized Controlled Trial [NCT04302402]Phase 2132 participants (Anticipated)Interventional2020-03-31Not yet recruiting
Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting. [NCT04910815]150 participants (Anticipated)Interventional2021-07-14Recruiting
Minimal Hepatic Encephalopathy is Associated With Increased Cerebral Vascular Resistance. a Transcranial Doppler Ultrasound Study [NCT04077125]100 participants (Actual)Observational2018-01-18Completed
A Phase 1, Single Arm, Open-Label Study to Evaluate the Effect of Rifaximin 550 MG Tablets TID on the Pharmacokinetics of Orally Administered Midazolam in Healthy Male and Female Volunteers [NCT00743912]Phase 124 participants (Actual)Interventional2008-09-30Completed
A Randomized, Double-blind, Placebo-controlled Trial of Rifaximin, a Non-absorbable Antibiotic, in the Treatment of Tropical Enteropathy [NCT00858988]147 participants (Actual)Interventional2007-09-30Completed
The Metabolic Consequences of Gastrointestinal Surgery [NCT02836353]81 participants (Actual)Interventional2017-01-31Terminated(stopped due to Reached scientific goals, further recruitment would not further advance the findings of study.)
Hemodynamic Response of Rifaximin and Non-selective β-blocker Combination Therapy Versus Non-selective β-blocker Monotherapy in Cirrhotic Patients With Esophageal Varices [NCT01897051]Phase 2/Phase 3140 participants (Anticipated)Interventional2013-07-31Recruiting
Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia [NCT00956397]55 participants (Actual)Interventional2007-08-31Completed
Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients: A Prospective, Multicenter, Randomized, Open-label, Controlled Phase III Study [NCT02011841]Phase 30 participants (Actual)Interventional2014-01-31Withdrawn(stopped due to We failed to recruit patients)
The Role of Breath Testing in Enriching the Likelihood of Response to Rifaximin in Patients With Diarrhea IBS [NCT03729271]Phase 4110 participants (Anticipated)Interventional2020-01-09Recruiting
Modulation of Gut Microbiota by Rifaximin in PD Patients [NCT03958708]Phase 1/Phase 220 participants (Anticipated)Interventional2019-05-13Recruiting
Evaluation of the Metabolome in Diverticular Disease and Effects of Probiotic Mixture VSL#3 vs Fibers, Rifaximin and Mesalazine on the Metabolome in Diverticular Disease of the Colon [NCT01831323]40 participants (Anticipated)Observational2012-12-31Recruiting
A Phase II, Multicentre, Double-blind, Randomised, Dose Range Finding Placebo Controlled Study of Rifaximin-EIR Tablet: Clinical Effectiveness and Tolerability in the Treatment of Moderate, Active Crohn's Disease [NCT00528073]Phase 2410 participants (Actual)Interventional2007-09-30Completed
A Multicenter, Double-blind, Placebo-controlled Randomized Clinical Trial Comparing Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites : Using or Not Using Rifaximin [NCT03069131]Phase 3160 participants (Actual)Interventional2018-03-20Completed
Prospective Pilot Study of the Effect of Rifaximin on B-Cell Dysregulation in Cirrhosis Due to Chronic Hepatitis C Infection [NCT01951209]13 participants (Actual)Interventional2016-11-17Terminated(stopped due to Inadequate enrollment prior to expiration date of unreplaceable blinded investigational product)
A Randomized Controlled Trial Evaluating Single-dose Rifaximin Versus Azithromycin With Loperamide Adjunct for Treatment of Acute Watery Diarrhea [NCT05677282]Phase 4150 participants (Anticipated)Interventional2022-10-28Recruiting
The Efficacy of Antibiotic Rifaximin on the Lipopolysaccharides (LPS) and Related Cytokine Levels in Non Alcoholic Fatty Liver Disease Patients [NCT02009592]42 participants (Actual)Interventional2013-06-30Completed
The Effects of Rifaximin Therapy in Patients Pre-Diagnosed With Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo Controlled Study [NCT02009618]500 participants (Actual)Interventional2013-01-31Completed
Double Blind Randomized Study, Comparing Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS [NCT02016196]Phase 3211 participants (Actual)Interventional2013-09-30Completed
A Placebo Controlled Single Centre Double Blind Randomised Trial to Investigate the Efficacy of Rifaximin Versus Placebo in Improving Systemic Inflammation and Neutrophil Malfunction in Patients With Cirrhosis and Chronic Hepatic Encephalopathy [NCT02019784]Phase 438 participants (Actual)Interventional2015-01-31Completed
Double-blind Randomized Controlled Trial of Rifaximin for Persistent Symptoms in Patients With Celiac Disease [NCT01137955]50 participants (Actual)Interventional2006-10-31Completed
The Potential Weight Loss Benefits of Rifaximin in an Intermittent Fasting Diet [NCT04674176]Phase 430 participants (Anticipated)Interventional2021-01-01Not yet recruiting
A Randomised, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Novel Rifaximin Formulations in Healthy Volunteers [NCT04529811]Phase 1124 participants (Actual)Interventional2020-09-24Completed
Prevention of Hepatic Encephalopathy by Administration of Rifaximin and Lactulose in Patients With Liver Cirrhosis Undergoing TIPS Placement: a Multi-centre Randomized, Double Blind, Placebo Controlled Trial. [NCT04073290]Phase 4238 participants (Anticipated)Interventional2020-01-21Recruiting
Fecal Microbial Transplant in Pediatric Crohn's Disease: A Double Blind Placebo Control Study [NCT02272868]Phase 1/Phase 27 participants (Actual)Interventional2015-01-31Terminated
Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease [NCT02738905]Early Phase 10 participants (Actual)Interventional2016-01-31Withdrawn(stopped due to insufficient support)
Could Rifaximin Modify the Pathogenesis of NAFLD? AMulticenter, Randomized, Double-Blind, Placebo-Controlled Trial [NCT02884037]50 participants (Actual)Observational2012-05-31Completed
Rifaximin Versus Norfloxacin in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis [NCT04159870]Phase 3322 participants (Anticipated)Interventional2019-11-05Active, not recruiting
Rifaximin Therapy Versus Low FODMAP Diet In Irritable Bowel Syndrome: A Randomised Controlled Trial [NCT04841980]Phase 4100 participants (Anticipated)Interventional2021-04-22Recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy [NCT01846663]Phase 46 participants (Actual)Interventional2013-04-03Terminated(stopped due to Study was determined to be infeasible.)
[NCT02163837]15 participants (Actual)Interventional2014-03-31Completed
Efficacy of Rafiximin in Patients With Cirrhotic Gastroesophageal Variceal Hemorrhage: A Single-center Pilot Study [NCT02991612]80 participants (Actual)Interventional2016-11-25Completed
A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications in Subjects With Early Decompensated Liver Cirrhosis [NCT01904409]Phase 2420 participants (Actual)Interventional2013-06-30Completed
[NCT01676597]80 participants (Anticipated)Interventional2012-09-30Recruiting
Use of Antibiotics to Eradicate Bacterial Pathogens Colonising the Colonic Mucosa in Ulcerative Colitis Patients [NCT00355602]40 participants (Anticipated)Interventional2006-07-31Completed
Effect of Rifaximin on Minimal Hepatic Encephalopathy and Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis [NCT02439307]11 participants (Actual)Interventional2017-02-28Terminated(stopped due to The study was terminated because of the reconversion of the hospital to care for patients with COVID19. For this reason, it was not possible to continue recruiting and monitoring patients for this clinical study.)
A Randomized, Double-Blind, Single Center, Comparative Dose Ranging Study of Rifaximin Vs. Placebo in the Prevention of Travelers' Diarrhea Due to Enteropathogenic Bacteria [NCT00098384]Phase 2220 participants Interventional2003-06-30Completed
Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Hemorrhage: A Multi-center Randomized Controlled Clinical Trial [NCT02964195]308 participants (Anticipated)Interventional2016-11-30Recruiting
Effect of Rifaximin on Driving Performance, Psychometric Test Performance and Quality of Life in Cirrhotic Patients With Minimal Hepatic Encephalopathy: Randomized, Double-blind, Placebo-controlled Trial. [NCT00533910]42 participants (Actual)Interventional2007-10-31Completed
Targeting Gut Microbiota for Motor Complications in Parkinson´s Disease [NCT04730245]Phase 114 participants (Actual)Interventional2018-06-01Completed
Safety and Tolerability of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis: a Multicenter, Double-blind, Placebo Controlled Randomized Clinical Trial. [NCT03150459]Phase 244 participants (Actual)Interventional2017-07-26Completed
A Randomized,Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Rifaximin for the Prevention of Travellers' Diarrhea [NCT00742469]Phase 3210 participants (Actual)Interventional2005-06-30Completed
Randomized Trial to Study the Effect of Rifaximin on Gut Microbiome Diversity Post Allogeneic Stem Cell Transplant in Acute Leukemia. [NCT06058572]Phase 2166 participants (Anticipated)Interventional2023-10-15Not yet recruiting
Rifaximin in the Treatment of Small Intestinal Bacterial Overgrowth and IBS: Double Blind Randomized Controlled Trial (Multicenter Trial) [NCT00259155]Phase 292 participants Interventional2003-07-31Completed
Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin. [NCT01842113]Phase 44 participants (Actual)Interventional2013-04-30Terminated(stopped due to PI Initiated study - PI left facility)
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess The Efficacy and Safety of Three Different Doses (275, 550 AND 1100 MG) of Rifaximin Administered BID For Either Two or Four Weeks in The Treatment of Patients With Diarrhea-Associa [NCT00269412]Phase 2525 participants (Anticipated)Interventional2005-12-31Completed
Use of Rifaximin in Patients With Functional Dyspepsia: A Randomized Controlled Trial [NCT01643083]Phase 2/Phase 395 participants (Actual)Interventional2013-01-31Completed
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. Phase A: Breath Testing and Colonic Transit in Hepatic Encephalopathy. Phase B: A Randomized Double Blind, Placebo Controlled Trial of Rifaximin for Hepatic Encepha [NCT00281502]Phase 250 participants (Anticipated)Interventional2005-12-31Recruiting
Prospective Randomized Double Blind Placebo Controlled Trial of Rifaximin 550mg PO Twice Daily for Three Months to Prevent Recurrent Fibrosis in Liver Transplant Recipients With Chronic Hepatitis C Virus Infection [NCT01603108]Phase 259 participants (Actual)Interventional2012-03-31Active, not recruiting
Rifaximin in Standard Three-Day Dosing With and Without the Antimotility Drug, Loperamide, in the Treatment of Travelers' Diarrhea [NCT00292344]Phase 4316 participants Interventional2004-06-30Completed
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety of Rifaximin for the Prevention of Travelers' Diarrhea in Subjects Traveling Outside the United States [NCT00328380]Phase 3660 participants (Anticipated)Interventional2005-12-31Completed
A Randomized, Double-Blind, Clinical Trial Evaluating Three Single Dose Regimens With Loperamide for Treatment of Ambulatory Watery Travelers' Diarrhea, and Azithromycin With and Without Loperamide for Treatment of Ambulatory Dysentery/Febrile Diarrhea [NCT01618591]384 participants (Actual)Interventional2012-09-30Terminated(stopped due to AWD arm was completed. ADF diarrhea arm was unable to fill completely and there are no funds remaining to continue recruiting/enrolling.)
Impact of Rifaximin on Liver Fibrosis in HIV-Infected Patients With Liver Disease [NCT01654939]Phase 40 participants (Actual)Interventional2012-10-31Withdrawn
"A Randomised Placebo Controlled Trial of Follow on Rifaximin for the Prevention of Relapse of Clostridium Associated Diarrhoea" [NCT01670149]Phase 4151 participants (Actual)Interventional2012-12-31Completed
Effect of Probiotic (Vivomixx/ DeSimone Formulation) on Gut Microbiome and Bacterial Translocation in Healthy Asian Volunteers - An Exploratory Randomized Controlled Trial [NCT05083572]Phase 432 participants (Anticipated)Interventional2021-03-10Recruiting
A Pilot Study of Xifaxan in Patients With Primary Sclerosing Cholangitis [NCT01695174]Phase 116 participants (Actual)Interventional2012-08-31Completed
Intestinal Decontamination With Rifaximin. Effects on the Inflammatory and Circulatory State in Patients With Cirrhosis and Ascites - A Randomised Controlled Clinical Study [NCT01769040]Phase 454 participants (Actual)Interventional2012-11-30Completed
Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement [NCT01773538]136 participants (Actual)Interventional2013-01-31Completed
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy [NCT01846806]10 participants (Actual)Interventional2012-09-30Terminated(stopped due to PI no longer at NYUMC)
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D) [NCT01543178]Phase 32,583 participants (Actual)Interventional2012-02-29Completed
A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing [NCT03219528]Phase 464 participants (Anticipated)Interventional2018-02-13Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis [NCT05297448]Phase 3466 participants (Anticipated)Interventional2022-08-03Recruiting
To Compare the Efficacy of (Rifaximin + Mebeverine), (Rifaximin + Amitriptyline), and (Rifaximin + Psyllium Husk) in Irritable Bowel Syndrome Associated With Diarrhea [NCT05867550]Phase 4162 participants (Actual)Interventional2023-01-03Completed
Rifaximin and Its Microbial Resistance as a Secondary Prophylaxis of Hepatic Encephalopathy in Patients With HCV Related Cirrhosis [NCT04736836]Phase 4100 participants (Actual)Interventional2015-01-31Completed
Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development: a Multicenter, Double-blind, Placebo Controlled Randomized Clinical Trial [NCT03780673]Phase 2/Phase 3254 participants (Actual)Interventional2019-01-03Completed
Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation [NCT03529825]Early Phase 126 participants (Actual)Interventional2018-07-18Completed
Open Label Study to Evaluate the Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy Subjects and Subjects With Severe Hepatic Impairment [NCT03818672]Phase 45 participants (Actual)Interventional2019-01-29Terminated(stopped due to Study determined to be infeasible.)
A Multicenter, Randomized, Open-Label, Active-Controlled, Trial to Evaluate the Safety and Efficacy of Rifaximin 550 mg With and Without Lactulose in Subjects With a History of Recurrent Overt Hepatic Encephalopathy [NCT01842581]Phase 4222 participants (Actual)Interventional2013-01-08Completed
A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks [NCT02240121]Phase 380 participants (Actual)Interventional2014-08-21Terminated(stopped due to The study was terminated early due to difficulty in enrollment and lack of clinical study drug access.)
Impact of Rifaximin Therapy on Intestinal Byproducts in Chronic Kidney Disease [NCT02342639]Phase 438 participants (Actual)Interventional2015-06-30Completed
Microbiota Intervention to Change the Response of Parkinson's Disease [NCT03575195]Phase 1/Phase 286 participants (Anticipated)Interventional2019-07-15Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis [NCT05071716]Phase 3466 participants (Anticipated)Interventional2022-04-07Recruiting
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rifaximin Vaginal Tablets in the Treatment of Bacterial Vaginosis [NCT02376972]Phase 2392 participants (Actual)Interventional2015-04-30Terminated(stopped due to According to the Recommendation of the Indipendent Data Monitoring Committee)
Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy: A Randomized Open Controlled Study [NCT03077217]Phase 440 participants (Actual)Interventional2017-05-01Completed
High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit-A Randomized Controlled Trial [NCT03115697]0 participants (Actual)Interventional2018-04-07Withdrawn(stopped due to lack of funds)
Effectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Endoscopic Recurrence in Crohn's Disease Patients With Risk Factor for Recurrence: A Multicenter Randomized Controlled Trial [NCT03185611]Phase 3120 participants (Anticipated)Interventional2017-05-18Recruiting
Pilot Study of Oral Rifaximin in Patients With Monoclonal Gammopathy [NCT03820817]Phase 148 participants (Anticipated)Interventional2019-05-15Recruiting
Rifaximin Delayed Release (400 mg Tablet) for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications. A Phase II, Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial [NCT03469050]Phase 2/Phase 3193 participants (Actual)Interventional2018-07-02Terminated(stopped due to Sponsor's decision)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Rifaximin 200-mg Tablets With Xifaxan® 200-mg Tablets in the Treatment of Travelers' Diarrhea [NCT02498418]Phase 3739 participants (Actual)Interventional2016-01-06Completed
Weight Loss in Parkinson's Disease and the Potential Role of Small Bowel Bacterial Overgrowth [NCT01662791]Phase 349 participants (Actual)Interventional2012-09-30Completed
A Double Blind Randomized Placebo Controlled Study Examining the Effects of a Non-Absorbable (Rifaximin) Antibiotic on the Chronic Immune Activation Observed In HIV-infected Subjects [NCT01866826]Phase 1/Phase 246 participants (Actual)Interventional2013-01-18Completed
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy [NCT01466595]Phase 273 participants (Actual)Interventional2011-09-30Completed
Evaluation of the Therapeutic Effect of Rifaximin on Covert Hepatic Encephalopathy With Underlying Small Intestinal Bacterial Overgrowth and Gastrointestinal Dysmotility in Liver Cirrhosis Patients [NCT04244877]Phase 30 participants (Actual)Interventional2021-09-15Withdrawn(stopped due to Study was unable to recruit participants..)
Double-blind, Placebo Controlled Trial Comparing Neomycin to Rifaximin Plus Neomycin in the Treatment of Methane Positive Subjects With Constipation-predominant Irritable Bowel Syndrome [NCT00945334]37 participants (Actual)Interventional2009-08-31Completed
Effects of Rifaximin on Visceral Hypersensitivity in Irritable Bowel Syndrome [NCT03462966]Phase 24 participants (Actual)Interventional2018-07-01Terminated(stopped due to recruitment challenges)
Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection [NCT02555293]Phase 296 participants (Anticipated)Interventional2016-02-29Terminated(stopped due to Prematurely terminated due to organisational reasons)
A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans [NCT01542541]68 participants (Actual)Interventional2011-07-31Completed
Dietary Fat, Lipoprotein and Lipopolysaccharide: Role in Insulin Resistance [NCT02124512]Phase 212 participants (Actual)Interventional2015-03-31Completed
Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth? [NCT00619970]115 participants (Actual)Interventional2007-02-28Completed
[NCT02321371]73 participants (Actual)Interventional2014-10-19Completed
PROSPER: Prospective Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin-α (TARGAXAN®/XIFAXAN®) 550 mg [NCT02488993]389 participants (Actual)Observational [Patient Registry]2015-06-30Completed
"Effect of Administration Add on of Rifaximin on Portal Hypertension of Patients With Liver Cirrhosis and Esophageal Varices in Standard Therapy With Propranolol" [NCT02508623]Phase 360 participants (Anticipated)Interventional2015-07-31Recruiting
A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks [NCT02240108]Phase 381 participants (Actual)Interventional2014-10-28Terminated(stopped due to The study was terminated early due to difficulty in enrollment and lack of clinical study drug access.)
Methane Production and Glycemic Regulation in Pre-diabetic Subjects: Role of Methane in Glycemic Control [NCT01638429]Early Phase 111 participants (Actual)Interventional2012-04-30Completed
Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni [NCT02280044]Phase 2/Phase 330 participants (Actual)Interventional2014-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00269399 (2) [back to overview]Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea.
NCT00269399 (2) [back to overview]Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success
NCT00298038 (6) [back to overview]Mean Change From Baseline In Fatigue Domain Score On The CLDQ At End Of Treatment
NCT00298038 (6) [back to overview]Mean Change From Baseline In Venous Ammonia Concentration At End Of Treatment
NCT00298038 (6) [back to overview]Time To Any Increase From Baseline In Asterixis Grade
NCT00298038 (6) [back to overview]Time To Any Increase From Baseline In Conn Score
NCT00298038 (6) [back to overview]Time To First HE-related Hospitalization
NCT00298038 (6) [back to overview]Time To The First Breakthrough Overt HE Episode
NCT00533910 (3) [back to overview]Total Sickness Impact Profile Score
NCT00533910 (3) [back to overview]Psychometric Test Performance
NCT00533910 (3) [back to overview]Driving Performance
NCT00619970 (2) [back to overview]The Number of Participants at Baseline With SIBO
NCT00619970 (2) [back to overview]Number of Participants With SIBO at Baseline (Week 0) and at 2 Week Post Treatment
NCT00680836 (6) [back to overview]Change in Stool Frequency (Number of Bowel Movements Per Day)
NCT00680836 (6) [back to overview]Change in Stool Consistency
NCT00680836 (6) [back to overview]Change in Bowel Urgency
NCT00680836 (6) [back to overview]Change in Bloating
NCT00680836 (6) [back to overview]Change in Abdominal Pain With Bowel Movement
NCT00680836 (6) [back to overview]Global Improvement Scale
NCT00686920 (4) [back to overview]Number Of Participants With A Significant Mean Change From Baseline In Vital Signs
NCT00686920 (4) [back to overview]Change From Baseline In Conn Score At Last Assessment
NCT00686920 (4) [back to overview]Number Of Participants Reporting A Non-serious Adverse Event Or A Serious Adverse Event
NCT00686920 (4) [back to overview]Number Of Participants With Postbaseline Potentially Clinically Significant Laboratory (Hematology and Blood Chemistry) Abnormal Results In ≥5% of Participants
NCT00724126 (2) [back to overview]Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6)
NCT00724126 (2) [back to overview]Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).
NCT00731679 (2) [back to overview]Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).
NCT00731679 (2) [back to overview]Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).
NCT00742469 (1) [back to overview]Cumulative Occurrence of Travellers' Diarrhea (TD) for Rifaximin 600 mg QD Compared to Placebo Over 14 Days of Treatment
NCT00858988 (1) [back to overview]Difference in the Urinary L:M Ratio Before and After the Intervention
NCT00945334 (2) [back to overview]Severity of Constipation in Each Arm at Week 1 After Completion of Therapy
NCT00945334 (2) [back to overview]Change in Methane From Baseline
NCT01137955 (4) [back to overview]Week 12 Gastrointestinal Symptom Rating Scale (GSRS) Score
NCT01137955 (4) [back to overview]Week 2 Gastrointestinal Symptom Rating Scale (GSRS) Score
NCT01137955 (4) [back to overview]Baseline Gastrointestinal Symptom Rating Scale (GSRS) Score
NCT01137955 (4) [back to overview]Percentage of Participants With Abnormal Breath Test
NCT01355575 (3) [back to overview]Insulin Resistance
NCT01355575 (3) [back to overview]Hepatic Triglyceride Content
NCT01355575 (3) [back to overview]Serum Alanine Aminotransferase (ALT) Levels
NCT01466595 (43) [back to overview]Change in LPS From Week 4 to Week 8
NCT01466595 (43) [back to overview]Change in LPS From Week 4 to Week 12
NCT01466595 (43) [back to overview]Change in LPS From Baseline to Week 4
NCT01466595 (43) [back to overview]Change in IL-6 From Week 4 to Week 8
NCT01466595 (43) [back to overview]Change in IL-6 From Week 4 to Week 12
NCT01466595 (43) [back to overview]Change in IL-6 From Baseline to Week 4
NCT01466595 (43) [back to overview]Change in hsCRP From Week 4 to Week 8
NCT01466595 (43) [back to overview]Change in hsCRP From Week 4 to Week 12
NCT01466595 (43) [back to overview]Change in hsCRP From Baseline to Week 4
NCT01466595 (43) [back to overview]Change in D-dimer From Week 4 to Week 8
NCT01466595 (43) [back to overview]Change in D-dimer From Baseline to Week 4
NCT01466595 (43) [back to overview]Change in CD8+ T-cell Activation From Week 4 to Week 8
NCT01466595 (43) [back to overview]Change in CD8+ T-cell Activation From Baseline to Week 4
NCT01466595 (43) [back to overview]Change in CD4 Count From Week 4 to Week 8
NCT01466595 (43) [back to overview]Change in CD4 Count From Week 4 to Week 12
NCT01466595 (43) [back to overview]Change in CD4 Count From Baseline to Week 4
NCT01466595 (43) [back to overview]Change in CD4 Activation Percent From Week 4 to Week 8
NCT01466595 (43) [back to overview]Change in CD8+ T-cell Activation From Week 4 to Week 12
NCT01466595 (43) [back to overview]Change in %Ki67+ of CD4+ From Week 4 to Week 8
NCT01466595 (43) [back to overview]Change in %CD38+ of CD8+ From Week 4 to Week 8
NCT01466595 (43) [back to overview]Change in %HLA-DR+/CD38+ of CD4+ From Baseline to Week 4
NCT01466595 (43) [back to overview]Change in %Ki67+ of CD4+ From Baseline to Week 4
NCT01466595 (43) [back to overview]Change in %CD38+ of CD8+ From Week 4 to Week 12
NCT01466595 (43) [back to overview]Change in %Ki67+ of CD8+ From Baseline to Week 4
NCT01466595 (43) [back to overview]Change in %Ki67+ of CD8+ From Week 4 to Week 12
NCT01466595 (43) [back to overview]Change in %Ki67+ of CD8+ From Week 4 to Week 8
NCT01466595 (43) [back to overview]Change in CD38+ of CD8+ MFI From Baseline to Week 4
NCT01466595 (43) [back to overview]Change in Peripheral B7hi CD4+ T-cell From Baseline to Week 4
NCT01466595 (43) [back to overview]Change in %CD38+ of CD8+ From Baseline to Week 4
NCT01466595 (43) [back to overview]Change in %Ki67+ of CD4+ From Week 4 to Week 12
NCT01466595 (43) [back to overview]Change in %CD38+ of CD4+ From Week 4 to Week 8
NCT01466595 (43) [back to overview]Change in %CD38+ of CD4+ From Week 4 to Week 12
NCT01466595 (43) [back to overview]Change in %CD38+ of CD4+ From Baseline to Week 4
NCT01466595 (43) [back to overview]Change in D-dimer From Week 4 to Week 12
NCT01466595 (43) [back to overview]Change in Peripheral B7hi CD4+ T-cells From Week 4 to Week 12
NCT01466595 (43) [back to overview]Change in Peripheral B7hi CD4+ T-cells From Week 4 to Week 8
NCT01466595 (43) [back to overview]Change in sCD14 From Baseline to Week 4
NCT01466595 (43) [back to overview]Change in sCD14 From Week 4 to Week 12
NCT01466595 (43) [back to overview]Change in sCD14 From Week 4 to Week 8
NCT01466595 (43) [back to overview]Primary Adverse Events
NCT01466595 (43) [back to overview]Change in CD38+ of CD8+ MFI From Week 4 to Week 12
NCT01466595 (43) [back to overview]Change in CD38+ of CD8+ MFI From Week 4 to Week 8
NCT01466595 (43) [back to overview]Change in CD4 Activation Percent From Week 4 to Week 12
NCT01542541 (2) [back to overview]SUVmax of FDG in Each Colonic Segment
NCT01542541 (2) [back to overview]SUVavg in Each Colonic Segment
NCT01543178 (1) [back to overview]Repeat Treatment Responders
NCT01638429 (13) [back to overview]Total Cholesterol Levels Before and After Antibiotic Therapy
NCT01638429 (13) [back to overview]Number of Subjects Who Eradicated Methane on Breath Test
NCT01638429 (13) [back to overview]% Stool Dry Weight
NCT01638429 (13) [back to overview]Average Daily Caloric Loss in Stool
NCT01638429 (13) [back to overview]Bowel Symptoms - Abdominal Pain
NCT01638429 (13) [back to overview]Bowel Symptoms - Bloating
NCT01638429 (13) [back to overview]Bowel Symptoms - Constipation
NCT01638429 (13) [back to overview]Bowel Symptoms - Diarrhea
NCT01638429 (13) [back to overview]Bowel Symptoms - Straining
NCT01638429 (13) [back to overview]Gastric Emptying
NCT01638429 (13) [back to overview]Low Density Lipoprotein (LDL) Levels Before and After Antibiotic Therapy
NCT01638429 (13) [back to overview]Stool Methanogen Levels
NCT01638429 (13) [back to overview]Stool Total Bacteria Levels
NCT01662791 (9) [back to overview]Calories Consumed From Brief Block Food Frequency Questionnaire (FFQ)
NCT01662791 (9) [back to overview]Paffenbarger Physical Activity Questionnaire (PPAQ)
NCT01662791 (9) [back to overview]Weight Change in Case Group After Treatment
NCT01662791 (9) [back to overview]PD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case Group
NCT01662791 (9) [back to overview]PD-specific Quality of Life Questionnaire (PDQ-39)
NCT01662791 (9) [back to overview]Number of Subjects With Small Bowel Bacterial Overgrowth (SBBO)
NCT01662791 (9) [back to overview]Hospital Anxiety and Depression Scale (HADS)
NCT01662791 (9) [back to overview]Gastrointestinal Symptom Severity Index (GISSI) Over Time in Case Group
NCT01662791 (9) [back to overview]Gastrointestinal Symptom Severity Index (GISSI)
NCT01842581 (6) [back to overview]Number of Participants Who Were Hospitalized Due to HE Episode
NCT01842581 (6) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT01842581 (6) [back to overview]Change From Baseline in Critical Flicker Frequency (CFF) at Day 170
NCT01842581 (6) [back to overview]Change From Baseline in Total Chronic Liver Disease Questionnaire (CLDQ) Score at Day 170
NCT01842581 (6) [back to overview]Number of Participants Reporting a First Breakthrough HE Episode
NCT01842581 (6) [back to overview]Number of Participants Who Died Due to Any Reason
NCT01866826 (5) [back to overview]Number of Participants With Viral (HIV-1)-Ribonucleic Acid (RNA) Elevated by Greater Than 50 Copies/ml Plasma at the End of the Rifaximin or Placebo Phase
NCT01866826 (5) [back to overview]Number of Participants With Serious and Non-Serious Adverse Events
NCT01866826 (5) [back to overview]Changes in Soluble Markers of Inflammation Between the Placebo and Rifaximin Phases of the Study
NCT01866826 (5) [back to overview]Changes in Soluble Cluster of Differentiation 14 (sCD14) Levels Between the Placebo and Rifaximin Phases of the Study
NCT01866826 (5) [back to overview]Changes in Cellular Markers of Immune Activation Between the Placebo and Rifaximin Phases of the Study
NCT02124512 (2) [back to overview]Circulating LPS
NCT02124512 (2) [back to overview]Tissue Inflammation
NCT02163837 (5) [back to overview]Percentage of Slow Wave Sleep and REM Sleep
NCT02163837 (5) [back to overview]Number of Steps Walked Daily
NCT02163837 (5) [back to overview]Quality of Sleep
NCT02163837 (5) [back to overview]Sleep Efficiency
NCT02163837 (5) [back to overview]Total Sleep Time
NCT02240108 (11) [back to overview]Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1 and 2 Both) at Week 52
NCT02240108 (11) [back to overview]Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1 and 2 Both) Over Time
NCT02240108 (11) [back to overview]Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1) at Week 16
NCT02240108 (11) [back to overview]Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1) at Week 52
NCT02240108 (11) [back to overview]Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 2) at Week 16
NCT02240108 (11) [back to overview]Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 2) at Week 52
NCT02240108 (11) [back to overview]Number of Participants With Endoscopic Response at Week 52
NCT02240108 (11) [back to overview]Number of Participants With Endoscopic Response Between Week 16 and 17
NCT02240108 (11) [back to overview]Number of Participants With SES-CD Score of 0 at Week 52
NCT02240108 (11) [back to overview]Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1 and 2 Both) at Week 16
NCT02240108 (11) [back to overview]Number of Participants Who Achieved Clinical Remission (Defined as CDAI Score of <150) at Week 16
NCT02240121 (11) [back to overview]Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 2) at Week 16
NCT02240121 (11) [back to overview]Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1) at Week 52
NCT02240121 (11) [back to overview]Number of Participants Who Achieved Clinical Remission (Defined as CDAI Score of <150) at Week 16
NCT02240121 (11) [back to overview]Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1) at Week 16
NCT02240121 (11) [back to overview]Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1 and 2 Both) at Week 16
NCT02240121 (11) [back to overview]Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1 and 2 Both) at Week 52
NCT02240121 (11) [back to overview]Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1 and 2 Both) Over Time
NCT02240121 (11) [back to overview]Number of Participants With SES-CD Score of 0 at Week 52
NCT02240121 (11) [back to overview]Number of Participants With Endoscopic Response Between Week 16 and 17
NCT02240121 (11) [back to overview]Number of Participants With Endoscopic Response at Week 52
NCT02240121 (11) [back to overview]Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 2) at Week 52
NCT02280044 (2) [back to overview]Campylobacteriosis
NCT02280044 (2) [back to overview]Recrudescent Events
NCT02342639 (3) [back to overview]Change in Serum Trimethylamine N-oxide (TMAO)
NCT02342639 (3) [back to overview]Change in Serum Interleukin-6 (IL-6)
NCT02342639 (3) [back to overview]C-reactive Protein
NCT02498418 (4) [back to overview]Number of Participants Who Achieved Clinical Cure at TOC Visit (Within 24 to 72 Hours From the Time of Last Dose): Modified Intent-to-Treat (mITT) Population
NCT02498418 (4) [back to overview]Time to Last Unformed Stool (TLUS)
NCT02498418 (4) [back to overview]Percentage of Participants Who Achieved Microbiological Cure at TOC Visit (Within 24 to 72 Hours From the Time of Last Dose)
NCT02498418 (4) [back to overview]Number of Participants Who Achieved Clinical Cure at Test of Cure (TOC) Visit (Within 24 to 72 Hours From the Time of Last Dose): Per-Protocol (PP) Population
NCT03124199 (3) [back to overview]Tolerability of Treatment
NCT03124199 (3) [back to overview]Percentage of Participants With H.Pylori Infection Eradication
NCT03124199 (3) [back to overview]Compliance With Treatment of Patients That Completed the Study
NCT03462966 (3) [back to overview]Association of Urgency Symptom and Rectal Sensitivity Testing.
NCT03462966 (3) [back to overview]Mean Change in the Balloon Volume (Measured in Cubic Centimeter) That Leads to First Urge to Defecate.
NCT03462966 (3) [back to overview]Number of Participants With a Rise of Hydrogen <20 Parts Per Million Within 90 Minutes of Lactulose Ingestion.(Which is Considered Normal )
NCT03515044 (3) [back to overview]Time to Overt Hepatic Encephalopathy (OHE) Resolution Determined Using the Hepatic Encephalopathy Grading Instrument (HEGI), Defined as HEGI Score < 2
NCT03515044 (3) [back to overview]Time to Hospital Discharge
NCT03515044 (3) [back to overview]Time to Improvement in Hepatic Encephalopathy Grading Instrument (HEGI) Score, Defined as at Least One Grade Decrease (Improvement)
NCT03712280 (2) [back to overview]Number of Participants With Adverse Events by the End of the Trial
NCT03712280 (2) [back to overview]Ammonia Plasma Levels at Baseline and Day 5
NCT03818672 (3) [back to overview]Time of the Maximum Concentration (Tmax)
NCT03818672 (3) [back to overview]Area Under the Plasma Concentration Versus Time Curve (AUC) During the 12-hour Dose Interval
NCT03818672 (3) [back to overview]Maximum Observed Plasma Concentration (Cmax)
NCT03856359 (20) [back to overview]Change in Interleukin 4 (IL-4)
NCT03856359 (20) [back to overview]Change in Interleukin 2 (IL-2)
NCT03856359 (20) [back to overview]Change in Cognitive Performance on the Mini-Mental State Exam (MMSE)
NCT03856359 (20) [back to overview]Change in Glial Fibrillary Acidic Protein (GFAP)
NCT03856359 (20) [back to overview]Participants With Treatment Emergent Adverse Events as Reported by the Subject That Required a Change in Safety Measures
NCT03856359 (20) [back to overview]Change in ADAS Cog 11 Scores
NCT03856359 (20) [back to overview]Change in Interleukin 10 (IL-10)
NCT03856359 (20) [back to overview]Total Tau
NCT03856359 (20) [back to overview]Phosphorylated Tau
NCT03856359 (20) [back to overview]Number of Participants Experiencing Diarrhea Caused by Clostridium Difficile
NCT03856359 (20) [back to overview]Development of Clostridium Difficile Diarrhea
NCT03856359 (20) [back to overview]Changes in Interleukin 13 (IL-13) Following Treatment With Rifaximin
NCT03856359 (20) [back to overview]Change in Interleukin 5 (IL-5)
NCT03856359 (20) [back to overview]Change in Tumor Necrosis Factor a
NCT03856359 (20) [back to overview]Change in Tolerability as Measured by Number of Adverse Events (AE).
NCT03856359 (20) [back to overview]Change in Neurofilament Light (Nfl) Levels
NCT03856359 (20) [back to overview]Change in Interleukin 8 (IL-8)
NCT03856359 (20) [back to overview]Change in Interleukin 6 (IL-6)
NCT03856359 (20) [back to overview]Change in Interleukin 1B (IL-1B)
NCT03856359 (20) [back to overview]Changes From Baseline in Ammonia Level
NCT04557215 (3) [back to overview]Change in Stool Frequency
NCT04557215 (3) [back to overview]Change in Stool Form
NCT04557215 (3) [back to overview]Change in Abdominal Pain

Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea.

"Resolution or improvement of baseline signs and symptoms was assessed as~Absence of severe abdominal pain for 2 consecutive days at the test of cure (TOC) Visit (Day 14 +/-1);~Absence of fever (< 38°C/100.4°F) for 2 consecutive days at the TOC Visit; and~3 unformed (loose or watery) stools per day for at least 48 hours that was sustained through the TOC Visit." (NCT00269399)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Rifaximin Treatment Arm67
Vancomycin Comparator Arm73

[back to top]

Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success

Recurrence of CDAD was defined as diarrhea and a positive Clostridium difficile stool toxin assay that occurs after initial clinical success. (NCT00269399)
Timeframe: 42 days

InterventionParticipants (Count of Participants)
Rifaximin Treatment Arm61
Vancomycin Comparator Arm63

[back to top]

Mean Change From Baseline In Fatigue Domain Score On The CLDQ At End Of Treatment

The 29-item Chronic Liver Disease Questionnaire (CLDQ) questionnaire consists of the following domains: fatigue, activity, emotional function, abdominal symptoms, systemic symptoms, and worry. Participants ranked their level of fatigue by using a 7-point scale from the worst response (1, high degree of fatigue) to the best response (7, minimal fatigue). (NCT00298038)
Timeframe: Baseline, 6 months (End Of Treatment)

,
Interventionscore on a scale (Mean)
BaselineChange from Baseline
Placebo3.340.11
Rifaximin3.280.30

[back to top]

Mean Change From Baseline In Venous Ammonia Concentration At End Of Treatment

Venous blood samples (10 mL) were collected at Baseline/Randomization (Day 0) and Days 28, 84, and 168. Baseline value was the last available value prior to first dose of study drug, and end of treatment value was the last available post-baseline value during the treatment period. (NCT00298038)
Timeframe: Baseline, Month 6 (End Of Treatment)

,
Interventionmicrogram per deciliter (ug/dL) (Mean)
BaselineChange from Baseline
Placebo92.1-1.2
Rifaximin87.9-5.7

[back to top]

Time To Any Increase From Baseline In Asterixis Grade

Time to any increase in asterixis grade was computed as the number of days from the first dose of study drug to the initial occurrence of an increase from baseline in asterixis grade. Asterixis (flapping tremor) was determined with the participant holding both arms and forearms extended with wrists dorsiflexed and fingers open for ≥30 seconds per standard practice. Asterixis grade range: Grade 0 (no abnormal movement) to Grade 4 (almost continuous flapping motions). Participants who discontinued prior to experiencing an increase in asterixis grade and prior to completion of the 6-month treatment period were censored at the time of discontinuation. The number of events of the initial occurrence of an increase from baseline in asterixis grade during the treatment interval is presented. (NCT00298038)
Timeframe: Baseline up to 6 months

,
Interventionevents (Number)
0 to <28 Days28 to <56 Days56 to <84 Days84 to <140 Days140 to <168 Days≥168 Days
Placebo20154641
Rifaximin1377311

[back to top]

Time To Any Increase From Baseline In Conn Score

Time to any increase in Conn score (mental state grade) was computed as the number of days from the first dose of study drug to the initial occurrence of an increase from baseline in Conn score. Conn score range: Grade 0 (no behavioral abnormality) to Grade 4 (coma; unable to test mental state). Participants who discontinued prior to experiencing an increase in Conn score and prior to completion of the 6-month treatment period were censored at the time of discontinuation. The number of events of the initial occurrence of an increase from baseline in Conn score during the treatment interval is presented. (NCT00298038)
Timeframe: Baseline up to 6 months

,
Interventionevents (Number)
0 to <28 Days28 to <56 Days56 to <84 Days84 to <140 Days140 to <168 Days≥168 Days
Placebo2621151050
Rifaximin1759501

[back to top] [back to top]

Time To The First Breakthrough Overt HE Episode

Time to a breakthrough overt HE episode was the duration (number of days) from time of first dose of study drug to the first breakthrough overt HE episode. A breakthrough overt HE episode was defined as an increase of Conn score from Grade 0 or 1 to ≥2, or an increase in Conn and asterixis score of 1 grade each for those participants who entered the study with a Conn score of 0. Participants who completed the study and did not experience a breakthrough overt HE episode were censored at the time of their 6-month visit. Participants who terminated early for reasons other than a breakthrough overt HE episode were contacted at 6 months from randomization to determine if they had experienced a breakthrough overt HE event or other outcome. Participants without breakthrough overt HE were censored at the time of last contact or death, whichever was earlier. The number of events of a first breakthrough overt HE episode during the treatment interval is presented. (NCT00298038)
Timeframe: Baseline up to 6 Months (168 days)

,
Interventionevents (Number)
0 to <28 Days28 to <56 Days56 to <84 Days84 to <140 Days140 to <168 Days≥168 Days
Placebo2023141060
Rifaximin1346710

[back to top]

Total Sickness Impact Profile Score

Total score ranging from 0 through >100 at the end of drug/placebo. Higher score indicates worse QOL (NCT00533910)
Timeframe: 8 weeks

Interventionscore on a scale (Mean)
Placebo12
Rifaximin10

[back to top]

Psychometric Test Performance

Z score of combined cognitive tests at end of rifaximin/placebo; higher scores indicate better psychometric test performance (NCT00533910)
Timeframe: 8 weeks

InterventionZ scores (Mean)
Placebo0.46
Rifaximin1.19

[back to top]

Driving Performance

Total driving errors at the end of drug/placebo. Minimum is zero, maximum is not defined. Higher number indicates greater errors. (NCT00533910)
Timeframe: 8 weeks

Interventionraw number of driving errors (Mean)
Placebo7.6
Rifaximin5.5

[back to top]

The Number of Participants at Baseline With SIBO

(NCT00619970)
Timeframe: upon enrollment

InterventionParticipants (Count of Participants)
Healthy Control14
Children Receiving Rifaximin44
Children Receiving Placebo24

[back to top]

Number of Participants With SIBO at Baseline (Week 0) and at 2 Week Post Treatment

(NCT00619970)
Timeframe: baseline (week 0) and at 2 weeks post treatment

,
InterventionParticipants (Count of Participants)
At baseline2 weeks
Children Receiving Placebo2419
Children Receiving Rifaximin4437

[back to top]

Change in Stool Frequency (Number of Bowel Movements Per Day)

Change in stool frequency (number of bowel movements per day) compared from baseline to post treatment is measured. Number of bowel movements per day before treatment is subtracted from the number of bowel movements per day after treatment. The change in frequency has been reported in the outcomes table. (NCT00680836)
Timeframe: 2 weeks

InterventionBowel movements/ day (Mean)
Placebo Group-0.3
Active Group-0.1

[back to top]

Change in Stool Consistency

Change in Stool consistency from baseline to post treatment is measured. Bristol stool scale is used for this purpose. The scale ranges from a value of 1- 7; 1 being very hard stool to 7 being liquid stools. The change is measured for 1 week post-treatment and the average consistency is used for the purpose of measuring change from baseline. (NCT00680836)
Timeframe: 2 weeks

Interventionunits on a scale (BSS) (Mean)
Placebo Group-0.4
Active Group-0.3

[back to top]

Change in Bowel Urgency

Urgency in a bowel movements compared from baseline to post treatment was measured. Participants were asked to note if they had urgency at bowel movements (meaning if they had to rush to the restroom). They marked either 'yes' or 'no'. The percentage of the time they said yes was calculated for 7 days. The difference between baseline and post treatment urgency was calculated. (NCT00680836)
Timeframe: 2 weeks

Interventiondifference in percentage of 'Yes' (Mean)
Placebo Group0.0
Active Group-0.1

[back to top]

Change in Bloating

Bloating is measured on a scale from 0 to 4; 0 = no bloating to 4 = severe bloating. Change in bloating is calculated from baseline to post treatment. (NCT00680836)
Timeframe: 2 weeks

Interventionunits on a scale (Mean)
Placebo Group-0.2
Active Group-0.2

[back to top]

Change in Abdominal Pain With Bowel Movement

Severity of abdominal pain on a scale of 0 to 4 was measured; 0 meaning no pain to 4 meaning severe pain. Change in abdominal pain from baseline to post treatment was calculated. (NCT00680836)
Timeframe: 2 weeks

Interventionunits on a scale (Mean)
Placebo Group-0.3
Active Group-0.2

[back to top]

Global Improvement Scale

Improvement in Irritable Bowel Syndrome symptoms post treatment is measured. This scale is not measured at baseline. Participants are asked if their symptoms improved or got worse and to rate it on a scale of 1- 7 for seven days. Average score for 7 days is calculated. The Global improvement scale ranges from 1- 7. Score of 1-3 means the IBS symptoms got worse, 4 means no change and 5-7 means improvement in the IBS symptoms. (NCT00680836)
Timeframe: Measured for seven days at the end of 2 weeks treatment and average score is calculated

Interventionunits on a scale (Mean)
Placebo Group4.3
Active Group4.3

[back to top]

Number Of Participants With A Significant Mean Change From Baseline In Vital Signs

Vital signs were measured and included sitting blood pressure, heart rate, oral temperature, and weight. These were collected at each scheduled study visit. Participants were placed supine for 5 minutes prior to each assessment of vital signs. Baseline value was defined as last available value (including the applicable values from the participants who rolled over from Study RFHE3001) prior to the first dose of study drug. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module. (NCT00686920)
Timeframe: Baseline up to Month 36

InterventionParticipants (Count of Participants)
New Rifaximin0
Continuing Rifaximin0

[back to top]

Change From Baseline In Conn Score At Last Assessment

The assessment for change in mental status during the study was measured by the Conn score (also known as the West Haven score). The following scale was used in the Conn scoring system: Grade 0=No personality or behavioral abnormality detected. Grade 1=Trivial lack of awareness, euphoria, or anxiety; shortened attention span; or impairment of addition or subtraction. Grade 2=Lethargy; disorientation for time; obvious personality change; and inappropriate behavior. Grade 3=Somnolence to semi-stupor, responsive to stimuli; confused; gross disorientation; and bizarre behavior. Grade 4=Coma, unable to test mental state. Participants entered the study with a Conn score of 0 to 2. Baseline value was defined as last available value (including the applicable values from the participants who rolled over from Study RFHE3001) prior to the first dose of study drug. (NCT00686920)
Timeframe: Baseline up to Month 36

,
Interventionscore on a scale (Mean)
BaselineChange from Baseline
Continuing Rifaximin0.20.1
New Rifaximin0.4-0.1

[back to top]

Number Of Participants Reporting A Non-serious Adverse Event Or A Serious Adverse Event

A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module. (NCT00686920)
Timeframe: Baseline up to Month 36

,
InterventionParticipants (Count of Participants)
Non-Serious Adverse EventSerious Adverse Event
Continuing Rifaximin1549
New Rifaximin78158

[back to top]

Number Of Participants With Postbaseline Potentially Clinically Significant Laboratory (Hematology and Blood Chemistry) Abnormal Results In ≥5% of Participants

Hematology and blood chemistry with potentially significant values included: Hemoglobin <9, >18, or ≥3 (grams/deciliter [g/dL]) decrease from previous visit or ≥4 g/dL decrease from baseline; Hematocrit <0.27%, >0.54%, or ≥0.10% decrease from previous visit or ≥0.15% decrease from baseline; Platelets <50 or >400*10^9/(liter [L]); Prothrombin time 9 seconds above baseline or upper limit of normal range; International normalized ratio >1.7; White blood cells <2.0 or >12.0*10^9/L; Lymphocytes <13.5% or >70%; Glucose, random, serum <2.2 or >16.5 millimole (mmol)/L; Potassium ≤3.0 or ≥5.5 mmol/L; Direct bilirubin increases 3-fold from baseline or >85.5 micromole (umol)/L. Baseline value was defined as the last available value (including the applicable values from the participants who rolled over from Study RFHE3001) prior to the first dose of study drug. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module. (NCT00686920)
Timeframe: Baseline up to Month 36

,
InterventionParticipants (Count of Participants)
HemoglobinHematocritPlateletsProthrombin TimeInternational Normalized RatioWhite Blood CellsLymphocytesGlucose, random, serumPotassiumDirect Bilirubin
Continuing Rifaximin124678210875
New Rifaximin1512181624152481714

[back to top] [back to top]

Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).

"The primary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug.~Adequate relief of global IBS symptoms was defined as a response of yes to the following question, which was asked weekly (every 7 days): In regard to all your symptoms of IBS, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms? [Yes/No]" (NCT00724126)
Timeframe: 4 weeks

Interventionpercentage of responders (Number)
Placebo32.2
Rifaximin40.6

[back to top]

Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).

"The primary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of global IBS symptoms was defined as a response of yes to the following question, which was asked weekly (every 7 days): In regard to all your symptoms of IBS, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms? [Yes/No]" (NCT00731679)
Timeframe: 4 weeks

Interventionpercentage of responders (Number)
Placebo31.2
Rifaximin40.8

[back to top] [back to top]

Cumulative Occurrence of Travellers' Diarrhea (TD) for Rifaximin 600 mg QD Compared to Placebo Over 14 Days of Treatment

The efficacy of 14 days of rifaximin 600 mg once daily (QD) compared with placebo when taken by healthy subjects to prevent travelers' diarrhea (TD) resulting from all causes. (NCT00742469)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment Arm15
Placebo Arm48

[back to top]

Difference in the Urinary L:M Ratio Before and After the Intervention

To initiate the test, each child drank a 100 ml sugar solution containing 5 g lactulose, 1 g mannitol, 1 g sucralose, and 10 g sucrose. Children remained at the village research site for 4 h after ingestion of the sugar solution, during which time all of the child's urine was collected in a sterile cup with 10 mg merthiolate added to limit the bacterial degradation of excreted sugars. The reported values for normal L:M range from 0.03 to 0.12. A value of ≥0.10 was chosen to be indicative of tropical enteropathy. This test was performed at enrollment and then 28 days later. (NCT00858988)
Timeframe: 28 days

InterventionRatio of lactulose-to-mannitol (L:M) exc (Mean)
Rifaximin-0.01
Placebo0.02

[back to top]

Severity of Constipation in Each Arm at Week 1 After Completion of Therapy

"Visual analog scale (VAS) score for constipation:~Severity was rated using a VAS from 0 to 100 units (with 0 = no symptom and 100 = severe symptoms)." (NCT00945334)
Timeframe: 1 year

Interventionunits on a scale (Mean)
Group 161.2
Group 228.6

[back to top]

Change in Methane From Baseline

"Methane output was reported as methane in parts per million (ppm) on breath test:~Subjects fast for 12 h prior to a breath sample. Breath samples were collected via a Quintron dual bag collecting system and analyzed using a BreathTracker SC. Output was reported as methane in parts per million (ppm) after correction for alveolar sample quality using breath CO2 concentration." (NCT00945334)
Timeframe: Baseline (Day 0) and Final Visit (Day 44)

Interventionparts per million (Median)
Group 17.5
Group 215

[back to top]

Week 12 Gastrointestinal Symptom Rating Scale (GSRS) Score

Validated seven point questionnaire that assesses gastrointestinal symptoms for five symptom areas, including abdominal pain, reflux, indigestion, diarrhea, and constipation. Individual scores are calculated for each symptom area and the mean of the scores is used to derive an overall GSRS score. Scores range from 0-7, with higher scores indicating gastrointestinal discomfort. (NCT01137955)
Timeframe: Week 12

Interventionscore on a scale (Mean)
Rifaximin 400mg2.5
Placebo2.5

[back to top]

Week 2 Gastrointestinal Symptom Rating Scale (GSRS) Score

Validated seven point questionnaire that assesses gastrointestinal symptoms for five symptom areas, including abdominal pain, reflux, indigestion, diarrhea, and constipation. Individual scores are calculated for each symptom area and the mean of the scores is used to derive an overall GSRS score. Scores range from 0-7, with higher scores indicating gastrointestinal discomfort. (NCT01137955)
Timeframe: Week 2

Interventionscore on a scale (Mean)
Rifaximin 400mg2.3
Placebo2.4

[back to top]

Baseline Gastrointestinal Symptom Rating Scale (GSRS) Score

Validated seven point questionnaire that assesses gastrointestinal symptoms for five symptom areas, including abdominal pain, reflux, indigestion, diarrhea, and constipation. Individual scores are calculated for each symptom area and the mean of the scores is used to derive an overall GSRS score. Scores range from 0-7, with higher scores indicating gastrointestinal discomfort. (NCT01137955)
Timeframe: Baseline (week 0)

InterventionScore on a scale (Mean)
Rifaximin2.7
Placebo2.8

[back to top]

Percentage of Participants With Abnormal Breath Test

A breath test measures for small intestine bacterial overgrowth (SIBO). The breath test measures the amount of hydrogen exhaled after drinking a sugar (lactulose) solution. An abnormal breath test is defined as: 1) a rise in hydrogen of ≥20 parts per million (ppm) within 100 minutes, or 2) two peaks ≥20 ppm over baseline. (NCT01137955)
Timeframe: Up to 12 weeks

InterventionPercent of Participants (Number)
Rifaximin12
Placebo20

[back to top]

Insulin Resistance

"Hepatic and systemic insulin resistance assessed using the hyperinsulinaemic euglycaemic clamp method.~Measured in % Suppression of Endogenous Glucose Production (SEGP). Values reported are the value from baseline and value from 6 weeks Rifaximin treatment." (NCT01355575)
Timeframe: Baseline and 6 weeks (end of treatment)

Intervention% SEGP (Median)
Rifaximin Baseline35.2
Rifaximin After 6-weeks30

[back to top]

Hepatic Triglyceride Content

"In vivo proton magnetic resonance spectroscopy (1H MRS) to derive a T2-corrected triglyceride to water ratio (hepatic lipid content- intra-hepatocellular lipid (IHCL)).~The values reported are the values from baseline and the values from 6 weeks Rifaximin treatment." (NCT01355575)
Timeframe: Baseline and 6 weeks (end of treatment)

Intervention% hepatic lipid content (Median)
Rifaximin Baseline21.6
Rifaximin After 6-weeks24.8

[back to top]

Serum Alanine Aminotransferase (ALT) Levels

"Alanine aminotransferase (ALT) after 6-weeks of Rifaximin from baseline (end of treatment) and 12 weeks (6 weeks after end of treatment).~ALT values reported are the values from 6-weeks Rifaximin treatment compared to baseline, and ALT values from 12 weeks (after 6 weeks of SoC) compared to baseline." (NCT01355575)
Timeframe: Baseline, 6 weeks (end of treatment) and 12 weeks (6 weeks after end of treatment)

Interventioniu/L (Median)
Rifaximin for 6-weeks63
Standard of Care for 6-weeks83

[back to top]

Change in LPS From Week 4 to Week 8

Change in LPS from week 4 to week 8. (NCT01466595)
Timeframe: At weeks 4 and 8

Interventionlog10 pg/mL (Median)
Arm A: Treatment With Rifaximin-0.01
Arm B: No Study Treatment0.00

[back to top]

Change in LPS From Week 4 to Week 12

Change in LPS from week 4 to week 12. (NCT01466595)
Timeframe: At weeks 4 and 12

Interventionlog10 pg/mL (Median)
Arm A: Treatment With Rifaximin0.00
Arm B: No Study Treatment0.03

[back to top]

Change in LPS From Baseline to Week 4

Change in Lipopolysaccharide (LPS) from baseline to week 4, where baseline value is the average of pre-entry and entry (NCT01466595)
Timeframe: At baseline and 4 weeks

Interventionlog10 pg/mL (Median)
Arm A: Treatment With Rifaximin0.00
Arm B: No Study Treatment-0.01

[back to top]

Change in IL-6 From Week 4 to Week 8

Change in IL-6 from week 4 to week 8. (NCT01466595)
Timeframe: At weeks 4 and 8

Interventionlog10 pg/mL (Median)
Arm A: Treatment With Rifaximin-0.03
Arm B: No Study Treatment0.06

[back to top]

Change in IL-6 From Week 4 to Week 12

Change in IL-6 from week 4 to week 12. (NCT01466595)
Timeframe: At weeks 4 and 12

Interventionlog10 pg/mL (Median)
Arm A: Treatment With Rifaximin0.02
Arm B: No Study Treatment0.02

[back to top]

Change in IL-6 From Baseline to Week 4

Change in Interleukin (IL)-6 from baseline to week 4, where baseline value is the average of pre-entry and entry (NCT01466595)
Timeframe: At baseline and 4 weeks

Interventionlog10 pg/mL (Median)
Arm A: Treatment With Rifaximin-0.03
Arm B: No Study Treatment0.05

[back to top]

Change in hsCRP From Week 4 to Week 8

Change in hsCRP from week 4 to week 8. (NCT01466595)
Timeframe: At weeks 4 and 8

Interventionlog10 ng/mL (Median)
Arm A: Treatment With Rifaximin-0.05
Arm B: No Study Treatment0.23

[back to top]

Change in hsCRP From Week 4 to Week 12

Change in hsCRP from week 4 to week 12. (NCT01466595)
Timeframe: At weeks 4 and 12

Interventionlog10 ng/mL (Median)
Arm A: Treatment With Rifaximin0.09
Arm B: No Study Treatment0.04

[back to top]

Change in hsCRP From Baseline to Week 4

Change in High Sensitivity C-reactive Protein (Hs-CRP) from baseline to week 4, where baseline value is the average of pre-entry and entry (NCT01466595)
Timeframe: At baseline and 4 weeks

Interventionlog10 ng/mL (Median)
Arm A: Treatment With Rifaximin-0.08
Arm B: No Study Treatment-0.09

[back to top]

Change in D-dimer From Week 4 to Week 8

D-dimer is a fibrin degradation product (FDP), a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. (NCT01466595)
Timeframe: At weeks 4 and 8

Interventionlog10 ng/mL (Median)
Arm A: Treatment With Rifaximin-0.02
Arm B: No Study Treatment0.03

[back to top]

Change in D-dimer From Baseline to Week 4

"Change in D-dimer from baseline to week 4, where baseline value is the average of pre-entry and entry.~D-dimer is a fibrin degradation product (FDP), a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis." (NCT01466595)
Timeframe: At baseline and 4 weeks

Interventionlog10 ng/mL (Median)
Arm A: Treatment With Rifaximin0.00
Arm B: No Study Treatment-0.03

[back to top]

Change in CD8+ T-cell Activation From Week 4 to Week 8

Change in CD8+ T-cell activation percent co-expressing HLA-DR and CD38 from week 4 to week 8 (NCT01466595)
Timeframe: At weeks 4 and 8

Interventionpercentage HLA-DR+/CD38+ of CD8+ (Median)
Arm A: Treatment With Rifaximin0.08
Arm B: No Study Treatment-0.71

[back to top]

Change in CD8+ T-cell Activation From Baseline to Week 4

Change in CD8+ T-cell activation percent co-expressing HLA-DR and CD38 from baseline to week 4, where the baseline value is the average of pre-entry and entry values. (NCT01466595)
Timeframe: At baseline and 4 weeks

Interventionpercentage HLA-DR+/CD38+ of CD8+ (Median)
Arm A: Treatment With Rifaximin0.00
Arm B: No Study Treatment0.64

[back to top]

Change in CD4 Count From Week 4 to Week 8

Change in total CD4 T-cell count from week 4 to week 8 (NCT01466595)
Timeframe: At weeks 4 and 8

Interventioncells/mm3 (Median)
Arm A: Treatment With Rifaximin-9.50
Arm B: No Study Treatment-13.00

[back to top]

Change in CD4 Count From Week 4 to Week 12

Change in total CD4 T-cell count from week 4 to week 12 (NCT01466595)
Timeframe: At weeks 4 and 12

Interventioncells/mm3 (Median)
Arm A: Treatment With Rifaximin0.00
Arm B: No Study Treatment-5.50

[back to top]

Change in CD4 Count From Baseline to Week 4

Change in total CD4 T-cell from baseline to week 4, where baseline value is the average of pre-entry and entry (NCT01466595)
Timeframe: At baseline and 4 weeks

Interventioncells/mm3 (Median)
Arm A: Treatment With Rifaximin-3.00
Arm B: No Study Treatment11.25

[back to top]

Change in CD4 Activation Percent From Week 4 to Week 8

Change in CD4 activation percent co-expressing HLA-DR and CD38 from week 4 to week 8 (NCT01466595)
Timeframe: At weeks 4 and 8

Interventionpercentage HLA-DR+/CD38+ of CD4+ (Median)
Arm A: Treatment With Rifaximin0.17
Arm B: No Study Treatment-0.53

[back to top]

Change in CD8+ T-cell Activation From Week 4 to Week 12

Change in CD8+ T-cell activation percent co-expressing HLA-DR and CD38 from week 4 to week 12 (NCT01466595)
Timeframe: At weeks 4 and 12

Interventionpercentage HLA-DR+/CD38+ of CD8+ (Median)
Arm A: Treatment With Rifaximin-0.05
Arm B: No Study Treatment-0.77

[back to top]

Change in %Ki67+ of CD4+ From Week 4 to Week 8

Change in advanced flow percent Ki67+ of CD4+ from week 4 to week 8 (NCT01466595)
Timeframe: At weeks 4 and 8

Interventionpercentage Ki67+ of CD4+ (Median)
Arm A: Treatment With Rifaximin0.21
Arm B: No Study Treatment-0.01

[back to top]

Change in %CD38+ of CD8+ From Week 4 to Week 8

Change in advanced flow percent CD38+ of CD8+ from week 4 to week 8 (NCT01466595)
Timeframe: At weeks 4 and 8

Interventionpercentage CD38+ of CD8+ (Median)
Arm A: Treatment With Rifaximin-0.12
Arm B: No Study Treatment-1.20

[back to top]

Change in %HLA-DR+/CD38+ of CD4+ From Baseline to Week 4

Change in CD4 activation percent co-expressing HLA-DR and CD38 from baseline to week 4, where baseline value is the average of pre-entry and entry (NCT01466595)
Timeframe: At baseline and 4 weeks

Interventionpercentage HLA-DR+/CD38+ of CD4+ (Median)
Arm A: Treatment With Rifaximin-0.15
Arm B: No Study Treatment0.15

[back to top]

Change in %Ki67+ of CD4+ From Baseline to Week 4

Change in advanced flow percent Ki67+ of CD4+ from baseline to week 4, where baseline value is the average of pre-entry and entry (NCT01466595)
Timeframe: At baseline and 4 weeks

Interventionpercentage Ki67+ of CD4+ (Median)
Arm A: Treatment With Rifaximin-0.17
Arm B: No Study Treatment0.05

[back to top]

Change in %CD38+ of CD8+ From Week 4 to Week 12

Change in advanced flow percent CD38+ of CD8+ from week 4 to week 12 (NCT01466595)
Timeframe: At weeks 4 and 12

Interventionpercentage CD38+ of CD8+ (Median)
Arm A: Treatment With Rifaximin-0.93
Arm B: No Study Treatment-1.96

[back to top]

Change in %Ki67+ of CD8+ From Baseline to Week 4

Change in advanced flow percent Ki67+ of CD8+ from baseline to week 4, where baseline value is the average of pre-entry and entry (NCT01466595)
Timeframe: At baseline and 4 weeks

Interventionpercentage Ki67+ of CD8+ (Median)
Arm A: Treatment With Rifaximin-0.12
Arm B: No Study Treatment0.12

[back to top]

Change in %Ki67+ of CD8+ From Week 4 to Week 12

Change in advanced flow percent Ki67+ of CD8+ from week 4 to week 12 (NCT01466595)
Timeframe: At weeks 4 and 12

Interventionpercentage Ki67+ of CD8+ (Median)
Arm A: Treatment With Rifaximin0.13
Arm B: No Study Treatment-0.09

[back to top]

Change in %Ki67+ of CD8+ From Week 4 to Week 8

Change in advanced flow percent Ki67+ of CD8+ from week 4 to week 8 (NCT01466595)
Timeframe: At weeks 4 and 8

Interventionpercentage Ki67+ of CD8+ (Median)
Arm A: Treatment With Rifaximin0.11
Arm B: No Study Treatment-0.08

[back to top]

Change in CD38+ of CD8+ MFI From Baseline to Week 4

"Change in CD38+ of CD8+ MFI (Median Fluorescence Intensity) from baseline to week 4, where baseline value is the average of pre-entry and entry.~MFI measures the shift in fluorescence intensity of a population of cells. MFI values are based on control to demonstrate an increase or decrease in expression of the marker. MFI in this study was automatically calculated in FlowJo. The median is the relative intensity value below which 50% of the events are found. MFI is an arbitrary unit of relative intensity." (NCT01466595)
Timeframe: At baseline and 4 weeks

InterventionMFI (relative intensity) (Median)
Arm A: Treatment With Rifaximin0.00
Arm B: No Study Treatment0.03

[back to top]

Change in Peripheral B7hi CD4+ T-cell From Baseline to Week 4

Change in gut-homing percent B7hi+ of CD4+ from baseline to week 4, where baseline value is the average of pre-entry and entry (NCT01466595)
Timeframe: At baseline and 4 weeks

Interventionpercentage B7hi+ of CD4+ (Median)
Arm A: Treatment With Rifaximin-0.40
Arm B: No Study Treatment0.00

[back to top]

Change in %CD38+ of CD8+ From Baseline to Week 4

Change in advanced flow percent CD38+ of CD8+ from baseline to week 4, where baseline value is the average of pre-entry and entry (NCT01466595)
Timeframe: At baseline and 4 weeks

Interventionpercentage CD38+ of CD8+ (Median)
Arm A: Treatment With Rifaximin0.21
Arm B: No Study Treatment0.66

[back to top]

Change in %Ki67+ of CD4+ From Week 4 to Week 12

Change in advanced flow percent Ki67+ of CD4+ from week 4 to week 12 (NCT01466595)
Timeframe: At weeks 4 and 12

Interventionpercentage Ki67+ of CD4+ (Median)
Arm A: Treatment With Rifaximin0.14
Arm B: No Study Treatment-0.22

[back to top]

Change in %CD38+ of CD4+ From Week 4 to Week 8

Change in advanced flow percent CD38+ of CD4+ from week 4 to week 8 (NCT01466595)
Timeframe: At weeks 4 and 8

Interventionpercentage CD38+ of CD4+ (Median)
Arm A: Treatment With Rifaximin-0.84
Arm B: No Study Treatment1.00

[back to top]

Change in %CD38+ of CD4+ From Week 4 to Week 12

Change in advanced flow percent CD38+ of CD4+ from week 4 to week 12 (NCT01466595)
Timeframe: At weeks 4 and 12

Interventionpercentage CD38+ of CD4+ (Median)
Arm A: Treatment With Rifaximin-0.67
Arm B: No Study Treatment-0.54

[back to top]

Change in %CD38+ of CD4+ From Baseline to Week 4

Change in advanced flow percent CD38+ of CD4+ from baseline to week 4, where baseline value is the average of pre-entry and entry (NCT01466595)
Timeframe: At baseline and 4 weeks

Interventionpercentage CD38+ of CD4+ (Median)
Arm A: Treatment With Rifaximin0.89
Arm B: No Study Treatment0.91

[back to top]

Change in D-dimer From Week 4 to Week 12

D-dimer is a fibrin degradation product (FDP), a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. (NCT01466595)
Timeframe: At weeks 4 and 12

Interventionlog10 ng/mL (Median)
Arm A: Treatment With Rifaximin-0.01
Arm B: No Study Treatment0.07

[back to top]

Change in Peripheral B7hi CD4+ T-cells From Week 4 to Week 12

Change in gut homing percent B7hi+ of CD4+ from week 4 to week 12 (NCT01466595)
Timeframe: At weeks 4 and 12

Interventionpercentage B7hi+ of CD4+ (Median)
Arm A: Treatment With Rifaximin-0.07
Arm B: No Study Treatment-0.19

[back to top]

Change in Peripheral B7hi CD4+ T-cells From Week 4 to Week 8

Change in gut homing percent B7hi+ of CD4+ from week 4 to week 8 (NCT01466595)
Timeframe: At weeks 4 and 8

Interventionpercentage B7hi+ of CD4+ (Median)
Arm A: Treatment With Rifaximin0.26
Arm B: No Study Treatment-0.02

[back to top]

Change in sCD14 From Baseline to Week 4

Change in soluble CD14 (sCD14) from baseline to week 4, where baseline value is the average of pre-entry and entry (NCT01466595)
Timeframe: At baseline and 4 weeks

Interventionlog10 ng/mL (Median)
Arm A: Treatment With Rifaximin-0.03
Arm B: No Study Treatment-0.03

[back to top]

Change in sCD14 From Week 4 to Week 12

Change in soluble CD14 from week 4 to week 12 (NCT01466595)
Timeframe: At weeks 4 and 8

Interventionlog10 ng/mL (Median)
Arm A: Treatment With Rifaximin0.03
Arm B: No Study Treatment0.02

[back to top]

Change in sCD14 From Week 4 to Week 8

Change in soluble CD14 from week 4 to week 8 (NCT01466595)
Timeframe: At weeks 4 and 8

Interventionlog10 ng/mL (Median)
Arm A: Treatment With Rifaximin-0.05
Arm B: No Study Treatment0.02

[back to top]

Primary Adverse Events

Primary adverse events include all SAEs, defined according to ICH guidelines and targeted protocol events (grade 2 or higher signs and symptoms, grade 2 or higher laboratory abnormality, all diagnoses identified by the ACTG criteria for clinical events, and all events that led to a change in treatment regardless of grade). (NCT01466595)
Timeframe: from study enrollment until study completion at 12 weeks

Interventionparticipants (Number)
Arm A: Treatment With Rifaximin27
Arm B: No Study Treatment9

[back to top]

Change in CD38+ of CD8+ MFI From Week 4 to Week 12

"Change in CD38+ of CD8+ median fluorescence intensity (MFI) from week 4 to week 12.~MFI measures the shift in fluorescence intensity of a population of cells. MFI values are based on control to demonstrate an increase or decrease in expression of the marker. MFI in this study was automatically calculated in FlowJo. The median is the relative intensity value below which 50% of the events are found. MFI is an arbitrary unit of relative intensity." (NCT01466595)
Timeframe: At weeks 4 and 12

InterventionMFI (relative intensity) (Median)
Arm A: Treatment With Rifaximin-0.02
Arm B: No Study Treatment-0.02

[back to top]

Change in CD38+ of CD8+ MFI From Week 4 to Week 8

"Change in CD38+ of CD8+ median fluorescence intensity (MFI) from week 4 to week 8.~MFI measures the shift in fluorescence intensity of a population of cells. MFI values are based on control to demonstrate an increase or decrease in expression of the marker. MFI in this study was automatically calculated in FlowJo. The median is the relative intensity value below which 50% of the events are found. MFI is an arbitrary unit of relative intensity." (NCT01466595)
Timeframe: At weeks 4 and 8

InterventionMFI (relative intensity) (Median)
Arm A: Treatment With Rifaximin0.08
Arm B: No Study Treatment-0.71

[back to top]

Change in CD4 Activation Percent From Week 4 to Week 12

Change in CD4 activation percent co-expressing HLA-DR and CD38 from week 4 to week 12 (NCT01466595)
Timeframe: At weeks 4 and 12

Interventionpercentage HLA-DR+/CD38+ of CD4+ (Median)
Arm A: Treatment With Rifaximin-0.14
Arm B: No Study Treatment-0.50

[back to top]

SUVmax of FDG in Each Colonic Segment

(NCT01542541)
Timeframe: Day 2

InterventionSUV (Mean)
Rifaximin4.6
Control4.3

[back to top]

SUVavg in Each Colonic Segment

(NCT01542541)
Timeframe: Day 2

InterventionSUV (Mean)
Rifaximin1.6
Control1.8

[back to top]

Repeat Treatment Responders

Subjects who respond to repeat treatment in both IBS-related abdominal pain and stool consistency. The proportion of patients who responded to repeat treatment during the first double-blind repeat treatment phase is presented. Response is defined as improvement from baseline in abdominal pain AND reduction from baseline in diarrhea. (NCT01543178)
Timeframe: 4-week treatment-free follow-up in double-blind repeat treatment phase.

Interventionpercentage of patients (Number)
Double-blind Rifaximin (Retreatment)32.6
Double-blind Placebo (Retreatment)25.0

[back to top]

Total Cholesterol Levels Before and After Antibiotic Therapy

"Total cholesterol levels were measured in all subjects before and after antibiotic treatment. After baseline (pre-treatment) testing, subjects underwent a 10-day course of antibiotics.Post-treatment blood samples were collected within 31 days (1 month) of completing the course of antibiotics. One subject received an exemption from this requirement and completed testing within 60 days.~For analysis, subjects were grouped into two groups:~Group 1 - Methane Eradicators (subjects who eradicated methane on breath test following antibiotic treatment) (N=8) Group 2 - Methane Non-eradicators (subjects who did not eradicate methane on breath test following antibiotic treatment) (N=3)" (NCT01638429)
Timeframe: Baseline and 1-60 days following completion of antibiotic treatment

,
Interventionmg/dL (Mean)
Pre-treatmentPost-treatment
Methane Eradicators192177
Methane Non-Eradicators173188

[back to top]

Number of Subjects Who Eradicated Methane on Breath Test

"Number of subjects who exhibited a decrease in breath methane levels to below detectable (below 3ppm) following antibiotic treatment.~After baseline (pre-treatment) testing, subjects underwent a 10-day course of antibiotics. Post-treatment breath tests were performed within 2 weeks (14 days) of completing the course of antibiotics." (NCT01638429)
Timeframe: Baseline and 1-14 days following completion of antibiotic treatment

Interventionparticipants (Number)
Obese/Overweight, Prediabetic Methane Positive8

[back to top]

% Stool Dry Weight

% stool dry weight [total stool dry weight (g)/total stool fresh weight (g)] was determined in all subjects before and after antibiotic treatment. After baseline (pre-treatment) testing, subjects underwent a 10-day course of antibiotics. Post-treatment stool samples were obtained within 31 days (1 month) of completing the course of antibiotics. One subject received an exemption from this requirement and completed testing within 60 days. For analysis, subjects were grouped into two groups: Group 1 - Total study population (methane eradicators and non-eradicators, N=11) Group 2 - Methane eradicators (subjects who eradicated methane on breath test following antibiotic treatment, N=8) (NCT01638429)
Timeframe: Baseline and 1-60 days following completion of antibiotic treatment

,
Intervention% stool dry weight (Mean)
Pre-treatmentPost-treatment
Methane Eradicators25.122.6
Total Study Population24.122.9

[back to top]

Average Daily Caloric Loss in Stool

"The daily caloric loss in stool for each subject was calculated by expressing the total number of kcalories lost in stool over a 3-day period as a percentage of the total number of kcalories ingested over the same 3 days (the number of calories ingested = the number available in meals provided less the number remaining in leftovers). Caloric content for meals, leftovers, and stool was determined by bomb calorimetry. This average daily caloric loss for each group was then compared before and after antibiotic therapy.~Post-treatment caloric harvest studies were performed within 31 days (1 month) of completing the course of antibiotics. One subject received an exemption from this requirement and completed testing within 60 days. For analysis, subjects were grouped into two groups:~Group 1 - Total study population (methane eradicators and non-eradicators, N=11) Group 2 - Methane eradicators (subjects who eradicated methane on breath test following antibiotic treatment, N=8)" (NCT01638429)
Timeframe: Baseline and 1-60 days following completion of antibiotic treatment

,
Intervention%kcal lost (Mean)
Pre-treatmentPost-treatment
Methane Eradicators8.38.3
Total Study Population8.18.3

[back to top]

Bowel Symptoms - Abdominal Pain

"Bowel symptom scores on a visual analog scale (VAS) were compared in all subjects before and after antibiotic treatment. Scale values were from 0 to 100, where 0 indicates no symptom and 100 indicates severe symptoms.~After baseline (pre-treatment) testing, subjects underwent a 10-day course of antibiotics. Post-treatment symptom scores were obtained within 31 days (1 month) of completing the course of antibiotics. One subject received an exemption from this requirement and completed testing within 60 days. For analysis, subjects were grouped into two groups:~Group 1 - Total study population (methane eradicators and non-eradicators, N=11) Group 2 - Methane eradicators (subjects who eradicated methane on breath test following antibiotic treatment, N=8)" (NCT01638429)
Timeframe: Baseline and 1-60 days following completion of antibiotic treatment

,
Intervention0-100mm visual analogue scale (Mean)
Pre-treatmentPost-treatment
Methane Eradicators28.621.6
Total Study Population23.3618.18

[back to top]

Bowel Symptoms - Bloating

"Bowel symptom scores on a visual analog scale (VAS) were compared in all subjects before and after antibiotic treatment. Scale values were from 0 to 100, where 0 indicates no symptom and 100 indicates severe symptoms.~After baseline (pre-treatment) testing, subjects underwent a 10-day course of antibiotics. Post-treatment symptom scores were obtained within 31 days (1 month) of completing the course of antibiotics. One subject received an exemption from this requirement and completed testing within 60 days. For analysis, subjects were grouped into two groups:~Group 1 - Total study population (methane eradicators and non-eradicators, N=11) Group 2 - Methane eradicators (subjects who eradicated methane on breath test following antibiotic treatment, N=8)" (NCT01638429)
Timeframe: Baseline and 1-60 days following completion of antibiotic treatment

,
Intervention0-100mm visual analogue scale (Mean)
Pre-treatmentPost-treatment
Methane Eradicators66.838.9
Total Study Population55.0939.91

[back to top]

Bowel Symptoms - Constipation

"Bowel symptom scores on a visual analog scale (VAS) were compared in all subjects before and after antibiotic treatment. Scale values were from 0 to 100, where 0 indicates no symptom and 100 indicates severe symptoms.~After baseline (pre-treatment) testing, subjects underwent a 10-day course of antibiotics. Post-treatment symptom scores were obtained within 31 days (1 month) of completing the course of antibiotics. One subject received an exemption from this requirement and completed testing within 60 days. For analysis, subjects were grouped into two groups:~Group 1 - Total study population (methane eradicators and non-eradicators, N=11) Group 2 - Methane eradicators (subjects who eradicated methane on breath test following antibiotic treatment, N=8)" (NCT01638429)
Timeframe: Baseline and 1-60 days following completion of antibiotic treatment

,
Intervention0-100mm visual analogue scale (Mean)
Pre-treatmentPost-treatment
Methane Eradicators31.022.3
Total Study Population30.1820.55

[back to top]

Bowel Symptoms - Diarrhea

"Bowel symptom scores on a visual analog scale (VAS) were compared in all subjects before and after antibiotic treatment. Scale values were from 0 to 100, where 0 indicates no symptom and 100 indicates severe symptoms.~After baseline (pre-treatment) testing, subjects underwent a 10-day course of antibiotics. Post-treatment symptom scores were obtained within 31 days (1 month) of completing the course of antibiotics. One subject received an exemption from this requirement and completed testing within 60 days. For analysis, subjects were grouped into two groups:~Group 1 - Total study population (methane eradicators and non-eradicators, N=11) Group 2 - Methane eradicators (subjects who eradicated methane on breath test following antibiotic treatment, N=8)" (NCT01638429)
Timeframe: Baseline and 1-60 days following completion of antibiotic treatment

,
Intervention0-100mm visual analogue scale (Mean)
Pre-treatmentPost-treatment
Methane Eradicators30.517.3
Total Study Population23.7314.64

[back to top]

Bowel Symptoms - Straining

"Bowel symptom scores on a visual analog scale (VAS) were compared in all subjects before and after antibiotic treatment. Scale values were from 0 to 100, where 0 indicates no symptom and 100 indicates severe symptoms.~After baseline (pre-treatment) testing, subjects underwent a 10-day course of antibiotics. Post-treatment symptom scores were obtained within 31 days (1 month) of completing the course of antibiotics. One subject received an exemption from this requirement and completed testing within 60 days. For analysis, subjects were grouped into two groups:~Group 1 - Total study population (methane eradicators and non-eradicators, N=11) Group 2 - Methane eradicators (subjects who eradicated methane on breath test following antibiotic treatment, N=8)" (NCT01638429)
Timeframe: Baseline and 1-60 days following completion of antibiotic treatment

,
Intervention0-100mm visual analogue scale (Mean)
Pre-treatmentPost-treatment
Methane Eradicators37.518.4
Total Study Population31.6421.55

[back to top]

Gastric Emptying

"Gastric Emptying times (minutes) were determined in all subjects before and after antibiotic treatment. After baseline (pre-treatment) testing, subjects underwent a 10-day course of antibiotics. Post-treatment gastric emptying studies were performed within 31 days (1 month) of completing the course of antibiotics. One subject received an exemption from this requirement and completed testing within 60 days. For analysis, subjects were grouped into two groups:~Group 1 - Total study population (methane eradicators and non-eradicators, N=11) Group 2 - Methane eradicators (subjects who eradicated methane on breath test following antibiotic treatment, N=8)" (NCT01638429)
Timeframe: Baseline and 1-60 days following completion of antibiotic treatment

,
Interventionminutes (Mean)
Pre-treatmentPost-treatment
Methane Eradicators174.9164.9
Total Study Population182.3163.5

[back to top]

Low Density Lipoprotein (LDL) Levels Before and After Antibiotic Therapy

"LDL levels were measured in all subjects before and after antibiotic treatment. After baseline (pre-treatment) testing, subjects underwent a 10-day course of antibiotics. Post-treatment blood samples were collected within 31 days (1 month) of completing the course of antibiotics. One subject received an exemption from this requirement and completed testing within 60 days.~For analysis, subjects were grouped into two groups:~Group 1 - Methane Eradicators (subjects who eradicated methane on breath test following antibiotic treatment) (N=8) Group 2 - Methane Non-eradicators (subjects who did not eradicate methane on breath test following antibiotic treatment) (N=3)" (NCT01638429)
Timeframe: Baseline and 1-60 days following completion of antibiotic treatment

,
Interventionmg/dL (Mean)
Pre-treatmentPost-treatment
Methane Eradicators116104
Methane Non-Eradicators96111

[back to top]

Stool Methanogen Levels

"Stool methanogen levels were measured in all subjects before and after antibiotic treatment. After baseline (pre-treatment) testing, subjects underwent a 10-day course of antibiotics. Post-treatment stool samples were collected within 31 days (1 month) of completing the course of antibiotics. One subject received an exemption from this requirement and completed testing within 60 days.~For analysis, subjects were grouped into two groups:~Group 1 - Methane Eradicators (subjects who eradicated methane on breath test following antibiotic treatment) (N=8) Group 2 - Methane Non-eradicators (subjects who did not eradicate methane on breath test following antibiotic treatment) (N=3)" (NCT01638429)
Timeframe: Baseline and 1-60 days following completion of antibiotic treatment

,
Interventioncolony forming units (Mean)
Pre-treatmentPost-treatment
Methane Eradicators3.6*10^71.1*10^5
Methane Non-Eradicators6.86*10^89.4*10^7

[back to top]

Stool Total Bacteria Levels

"Stool total bacteria levels were measured in all subjects before and after antibiotic treatment. After baseline (pre-treatment) testing, subjects underwent a 10-day course of antibiotics.Post-treatment stool samples were collected within 31 days (1 month) of completing the course of antibiotics. One subject received an exemption from this requirement and completed testing within 60 days. For analysis, subjects were grouped into two groups:~Group 1 - Methane Eradicators (subjects who eradicated methane on breath test following antibiotic treatment) (N=8) Group 2 - Methane Non-eradicators (subjects who did not eradicate methane on breath test following antibiotic treatment) (N=3)" (NCT01638429)
Timeframe: Baseline and 1-60 days following completion of antibiotic treatment

,
Interventioncolony forming units (Mean)
Pre-treatmentPost-treatment
Methane Eradicators1.1*10^91.2*10^9
Methane Non-Eradicators3.7*10^88.5*10^9

[back to top]

Calories Consumed From Brief Block Food Frequency Questionnaire (FFQ)

"The FFQ is a validated, self-administered semi-quantitative questionnaire used to assess differences in macronutrient, and energy intake. It was designed to provide estimates of usual and customary dietary intake. This questionnaire contains a food list of about 70 food items.~A Food Frequency Questionnaire (FFQ) is a limited checklist of foods and beverages with a frequency response section for subjects to report how often each item was consumed over a specified period of time. Semi-quantitative FFQs collect portion size information as standardized portions or as a choice of portion sizes. Calculations for nutrient intake or calories can be estimated via computerized software programs that multiply the reported frequency of each food by the amount of nutrient or calories in a serving of that food." (NCT01662791)
Timeframe: Baseline

,
InterventionCalories (Mean)
Total calories consumedFatSaturated FatProteinCarbohydrateAlcoholSweets
Case Group1503.736.312.713.445.114.810.9
Control Group1588.038.013.015.743.712.56.5

[back to top]

Paffenbarger Physical Activity Questionnaire (PPAQ)

"The PPAQ is a validated, self-administered questionnaire that asks for a recall of physical activity of physical activity over the previous 1-week. From the answers to the questions, a physical activity index (PAI) can be computed, providing an estimate of energy expenditure in kcal/week.~The PAI can be estimated using a list of the physical activities a person performs within a time period and the amount of time spent on each activity, e.g. walking to work, light housework, swimming, carrying bricks at work, or whatever applies to an individual person. There is a value called the physical activity ratio for each activity. The list of activities is used to find the relevant values of physical activity ratios, then an overall physical activity level value for the time period is calculated, using time-weighted averages of the physical activity ratios.~This assessment was only measured at baseline." (NCT01662791)
Timeframe: Baseline

Interventionkcal/week (Mean)
Case Group848.8
Control Group2253

[back to top]

Weight Change in Case Group After Treatment

Weight change after treatment (NCT01662791)
Timeframe: baseline, 3 months

Interventionparticipants (Number)
Subjects who lost weight from baselineSubjects who gained weight from baseline
Case Group35

[back to top]

PD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case Group

The PDQ-39 is designed to address aspects of functioning and well-being for those affected by Parkinson's disease. This questionnaire is based on a multi-dimensional model of health. Eight subscale scores may be derived from the items: mobility (10 items), activities of daily living (6 items), emotional well-being (6 items), stigma (4 items), social support (3 items), cognitions (4 items), communication (3 items), bodily discomfort (3 items). Patients are asked to think about their health and general well-being and to consider how often in the last month they have experienced certain events (e.g. difficulty walking 100 yards). Patients are asked to indicate the frequency of each event by selecting one of 5 options (Likert Scale): Never/occasionally/sometimes/often/always or cannot do at all. Each dimension is calculated as a scale from 0 to 100, with 0= no problem at all; 100= maximum level of problem. Sub-scale score are averaged to calculate the summary index. (NCT01662791)
Timeframe: Baseline and 3 months

Interventionunits on a scale (Mean)
Mobility baselineMobility 3 monthsActivities of Daily Living baselineActivities of Daily Living 3 monthsEmotional Well-Being baselineEmotional Well-Being 3 monthsStigma baselineStigma 3 monthsSocial Support baselineSocial Support 3 monthsCognition baselineCognition 3 monthsCommunication baselineCommunication 3 monthsBodily Discomfort baselineBodily Discomfort 3 monthsSummary Index baselineSummary Index 3 months
Case Group23.127.825.017.717.211.013.35.53.13.132.021.925.015.624.030.220.316.6

[back to top]

PD-specific Quality of Life Questionnaire (PDQ-39)

The PDQ-39 is designed to address aspects of functioning and well-being for those affected by Parkinson's disease. This questionnaire is based on a multi-dimensional model of health. Eight subscale scores may be derived from the items: mobility (10 items), activities of daily living (6 items), emotional well-being (6 items), stigma (4 items), social support (3 items), cognitions (4 items), communication (3 items), bodily discomfort (3 items). Patients are asked to think about their health and general well-being and to consider how often in the last month they have experienced certain events (e.g. difficulty walking 100 yards). Patients are asked to indicate the frequency of each event by selecting one of 5 options (Likert Scale): Never/occasionally/sometimes/often/always or cannot do at all. Each dimension is calculated as a scale from 0 to 100, with 0= no problem at all; 100= maximum level of problem. Sub-scale score are averaged to calculate the summary index. (NCT01662791)
Timeframe: baseline

,
Interventionunits on a scale (Mean)
MobilityActivities of Daily LivingEmotional Well-BeingStigmaSocial SupportCognitionCommunicationBodily DiscomfortSummary Index
Case Group23.125.017.213.33.132.025.024.020.3
Control Group14.018.113.26.21.417.510.827.013.5

[back to top]

Number of Subjects With Small Bowel Bacterial Overgrowth (SBBO)

SBBO is measured by the Hydrogen Breath Test, which measures the hydrogen and methane gas produced by bacteria in the small bowel that has diffused into the blood, then lungs for expiration. After an overnight fast, subjects ingested a solution consisting of 50 grams of glucose mixed in 150 mL of water. Immediately before ingestion of glucose and at 20-minute intervals for 2 hours following ingestion, laboratory staff collected end-expiratory breath samples and analyzed them for hydrogen and methane using a Quintron sample correction (SC) breath microlyzer. A diagnosis of SBBO was defined by an increase in expiration of 12 parts per million (ppm) or more of hydrogen and/or methane. (NCT01662791)
Timeframe: Baseline to 2 hours

,
Interventionparticipants (Number)
12 ppm increase20 ppm increase
Case Group22
Control Group129

[back to top]

Hospital Anxiety and Depression Scale (HADS)

The HADS is a self-administered 14-item questionnaire (seven for anxiety and seven for depression) Items are rated on a 4-point scale from 0-3 and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) for either anxiety or depression. The cut-offs used for identifying significant psychiatric distress was >/= 8. This assessment was only measured at baseline (NCT01662791)
Timeframe: Baseline

,
Interventionunits on a scale (Mean)
DepressionAnxiety
Case Group3.53.8
Control Group3.34.0

[back to top]

Gastrointestinal Symptom Severity Index (GISSI) Over Time in Case Group

The GISSI is a validated, self-administered, multi-dimensional instrument designed to measure the frequency, severity and bothersomeness of individual GI symptoms and to provide subscale scores for interrelated symptom clusters. Factor analyses yielded 5 distinct symptom clusters that were labeled as Constipation/Difficult defecation; Abdominal Pain/Discomfort; Dyspepsia; Diarrhea/Fecal incontinence; Gastroesophageal reflux disease (GERD)/Chest symptoms; and Nausea/Vomiting. Scores could range from 0 to 100, with a higher score indicating greater severity of symptoms. (NCT01662791)
Timeframe: baseline, 3 months

Interventionunits on a scale (Mean)
Constipation baselineConstipation 3 monthsDyspepsia baselineDyspepsia 3 monthsAbdominal Pain/Discomfort baselineAbdominal Pain/Discomfort 3 monthsDiarrhea baselineDiarrhea 3 monthsGERD baselineGERD 3 monthsNausea/Vomiting baselineNausea/Vomiting 3 months
Case Group32.310.012.98.214.54.06.012.710.08.55.82.2

[back to top]

Gastrointestinal Symptom Severity Index (GISSI)

The GISSI is a validated, self-administered, multi-dimensional instrument designed to measure the frequency, severity and bothersomeness of individual GI symptoms and to provide subscale scores for interrelated symptom clusters. Factor analyses yielded 5 distinct symptom clusters that were labeled as Constipation/Difficult defecation; Abdominal Pain/Discomfort; Dyspepsia; Diarrhea/Fecal incontinence; Gastroesophageal reflux disease (GERD)/Chest symptoms; and Nausea/Vomiting. Scores could range from 0 to 100, with a higher score indicating greater severity of symptoms. (NCT01662791)
Timeframe: Baseline

,
Interventionunits on a scale (Mean)
ConstipationDyspepsiaAbdominal Pain/DiscomfortDiarrheaGERDNausea/Vomiting
Case Group22.67.28.13.45.61.6
Control Group14.54.56.62.73.40.63

[back to top]

Number of Participants Who Were Hospitalized Due to HE Episode

An HE-related hospitalization was defined as a hospitalization directly resulting from HE, or when HE events occurred during hospitalization. The time to first HE-related hospitalization was defined as the duration between the date of first dose of study drug and the date of first HE-related hospitalization. Number of participants who were hospitalized due to HE episode during randomization to Month 6 is presented. (NCT01842581)
Timeframe: From randomization (Day 1) up to Day 170

InterventionParticipants (Count of Participants)
Rifaximin 550 mg BID23
Rifaximin 550 mg BID + Lactulose14

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAE was defined as an AE that occurred from first dose of study drug until last dose of study drug plus 5 days (for non-fatal AEs) or plus 30 days (for fatal AEs).A summary of non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. (NCT01842581)
Timeframe: From randomization (Day 1) up to end of study (Day 186)

InterventionParticipants (Count of Participants)
Rifaximin 550 mg BID99
Rifaximin 550 mg BID + Lactulose81

[back to top]

Change From Baseline in Critical Flicker Frequency (CFF) at Day 170

The critical flicker frequency (CFF), a validated assessment of neurological function was assessed using a specialized CFF instrument. The CFF is the frequency at which the participant observes a constant light transition to a flickering light and was measured in Hertz. The CFF was measured on a continuous scale and was the mean of 8 separate fusion-to-flicker transition tests performed in rapid succession. Increases in CFF results represent improvement in neurological function in participants with HE. (NCT01842581)
Timeframe: Baseline, Day 170

,
Interventionhertz (Mean)
BaselineChange at Day 170
Rifaximin 550 mg BID35.141.09
Rifaximin 550 mg BID + Lactulose34.642.10

[back to top]

Change From Baseline in Total Chronic Liver Disease Questionnaire (CLDQ) Score at Day 170

CLDQ was used to measure health-related quality of life. CLDQ includes 29 items in the following 6 domains: abdominal symptoms (3 items), fatigue (5 items), systemic symptoms (5 items), activity (3 items), emotional function (8 items), and worry (5 items). All items were measured on a 7-point Likert scale, ranging from 0 to 6 with higher values indicating better quality of life. Each domain score of CLDQ was calculated as the mean of the responses of items in that domain. Overall CLDQ score was obtained by adding scores for each item and dividing by the total number of items. Overall CLDQ score ranged from 0 (most impairment) to 6 (least impairment) with higher scores indicating better quality of life. If at least half of the items were non-missing for a domain, mean values of the non-missing items for that domain were used as imputed values for missing values. If more than half of the items in a domain were missing, no values were imputed and domain score was considered as missing. (NCT01842581)
Timeframe: Baseline, Day 170

,
Interventionunits on a scale (Mean)
BaselineChange at Day 170
Rifaximin 550 mg BID4.130.29
Rifaximin 550 mg BID + Lactulose4.260.08

[back to top]

Number of Participants Reporting a First Breakthrough HE Episode

A breakthrough HE episode was defined as an increase of the Conn score to Grade greater than or equal to (≥) 2 (ie, 0 or 1 to ≥ 2). Conn score is widely used as a measure of mental state in HE. The scale used in Conn scoring system include: Grade 0=No personality or behavioral abnormality; Grade 1=Trivial lack of awareness, euphoria, or anxiety; shortened attention span, impairment of addition or subtraction; Grade 2=Lethargy, disorientation for time, obvious personality change, inappropriate behaviour; Grade 3=Somnolence to semi-stupor, responsive to stimuli, confused, gross disorientation, bizarre behaviour; Grade 4=Coma, unable to test mental state. The time to the first breakthrough HE episode was defined as the duration between the date of first dose of study drug and the date of first breakthrough HE episode. Number of participants reporting a first breakthrough HE episode during randomization to Month 6 is presented. (NCT01842581)
Timeframe: From randomization (Day 1) up to Day 170

InterventionParticipants (Count of Participants)
Rifaximin 550 mg BID28
Rifaximin 550 mg BID + Lactulose15

[back to top]

Number of Participants Who Died Due to Any Reason

(NCT01842581)
Timeframe: From randomization (Day 1) up to end of study (Day 186)

InterventionParticipants (Count of Participants)
Rifaximin 550 mg BID2
Rifaximin 550 mg BID + Lactulose2

[back to top]

Number of Participants With Viral (HIV-1)-Ribonucleic Acid (RNA) Elevated by Greater Than 50 Copies/ml Plasma at the End of the Rifaximin or Placebo Phase

HIV-1-RNA levels were assessed by using the single copy assay or the traditional HIV Branched Deoxyribonucleic Acid bDNA assay to determine elevations in HIV-1 RNA >50 copies/ml plasma at the end of the Rifaximin or placebo phase. Differences were tested by using both the Wilcoxon and the t-test. (NCT01866826)
Timeframe: Between Day 28 of Treatment Phase 1 and Day 28 of Treatment Phase 2

InterventionParticipants (Count of Participants)
Rifaximin0
Placebo0

[back to top]

Number of Participants With Serious and Non-Serious Adverse Events

The number of participants with serious and non-serious adverse events that were possibly related to Rifaximin or Placebo as assessed by the Division of Acquired Immune Deficiency Syndrome (AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0 A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01866826)
Timeframe: From baseline until up to approximately 14 weeks

InterventionParticipants (Count of Participants)
Rifaximin12
Placebo11

[back to top]

Changes in Soluble Markers of Inflammation Between the Placebo and Rifaximin Phases of the Study

Changes in soluble marker of inflammation Interleukin 6 (IL6) between the placebo and rifaximin phases of the study. Differences will be tested by using both the Wilcoxon and the t-test. (NCT01866826)
Timeframe: Between Day 28 of Treatment Phase 1 and Day 28 of Treatment Phase 2

Interventionpicograms/milliliter (Mean)
Rifaximin7.94
Placebo8.10

[back to top]

Changes in Soluble Cluster of Differentiation 14 (sCD14) Levels Between the Placebo and Rifaximin Phases of the Study

One sample Wilcoxon statistic was applied to evaluate the difference on treatment phases between the placebo and Rifaximin. (NCT01866826)
Timeframe: Between Day 28 of Treatment Phase 1 and Day 28 of Treatment Phase 2

Interventionmcg/mL (Mean)
Rifaximin0.0067
Placebo0.0035

[back to top]

Changes in Cellular Markers of Immune Activation Between the Placebo and Rifaximin Phases of the Study

Changes in cellular markers of immune activation (IA) is defined as changes in the percentage of cluster of differentiation 4 (CD4) + or cluster of differentiation 8 (CD8)+ T cells that express human leukocyte antigen - antigen D Related (HLA-DR) and cluster of differentiation 38 (CD38). Differences will be tested by using both the Wilcoxon and the t-test. (NCT01866826)
Timeframe: Between Day 28 of Treatment Phase 1 and Day 28 of Treatment Phase 2

Interventionpercentage of lymphocytes (Mean)
Rifaximin10.00
Placebo9.92

[back to top]

Circulating LPS

Plasma lipopolysaccharide (LPS) will be measured both in the fasting state and after a lipid-rich meal in obese subjects (Pre-Treatment: 0, 4 and 8 hr timepoints). The subjects will then be treated with the antibiotic rifaximin for 12 weeks to substantially reduce gut bacteria. LPS measurements at fasting and after a lipid-rich meal will be repeated (Post-Treatment: 0, 4 and 8 hr timepoints). The lipid tolerance tests before and after treatment with rifaximin will be assessed to determine whether there is a reduction in post-prandial LPS. LPS measurements were obtained using a modified LAL Assay. (NCT02124512)
Timeframe: 0, 4 and 8 hours at Baseline, and 0, 4 and 8 hours after 12 weeks of treatment

,
InterventionEU/mL (Mean)
Pre-treatment 0hrPre-treatment 4hrPre-treatment 8hrPost-treatment 0hrPost-treatment 4hrPost-treatment 8hr
Arm 1 Rifaximin SSD2.4413.661.711.898.452.14
Arm 2 Placebo1.8610.001.041.869.972.29

[back to top]

Tissue Inflammation

Subjects will undergo a baseline fat biopsy (pre-treatment). They will then be treated with rifaximin for 12 weeks and biopsies will be repeated to determine if disruption of the microbiota reduces tissue inflammation. Data are reported as normalized mRNA expression levels (arbitrary units) of TNFalpha. (NCT02124512)
Timeframe: Pre-Treatment (baseline) and Post-Treatment (12 weeks after baseline).

,
Interventionarbitrary units (Mean)
Pre-TreatmentPost-Treatment
Arm 1 Rifaximin SSD2.001.67
Arm 2 Placebo1.301.46

[back to top]

Percentage of Slow Wave Sleep and REM Sleep

sum of percentage of sleep spent in slow wave sleep and REM sleep during sleep per 24h ; assessed by 24-h polysomnography (NCT02163837)
Timeframe: 28 days

Interventionpercentage of total sleep time per 24h (Mean)
Rifaximine56

[back to top]

Number of Steps Walked Daily

number of steps walked daily assessed by actigraphy (measure of physical activity) (NCT02163837)
Timeframe: 28 days

Interventionsteps per day (Median)
Rifaximine905

[back to top]

Quality of Sleep

assessed by Pittsburgh sleep quality index questionnaire (PSQI). Values: 0 to 21. 21= worse sleep quality (NCT02163837)
Timeframe: 28 days

Interventionunits on a scale (Mean)
Rifaximine9

[back to top]

Sleep Efficiency

total sleep time/ time spent in bed per 24h, expressed in percentage of time spent in bed, assessed by actigraphy (NCT02163837)
Timeframe: 28 days

Interventionpercentage (Mean)
Rifaximine75

[back to top]

Total Sleep Time

total sleep time/ 24h, measured in minutes, by actigraphy (NCT02163837)
Timeframe: 28 days

Interventionminutes (Median)
Rifaximine446

[back to top]

Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1 and 2 Both) at Week 52

Clinical Symptom Remission defined by (1) the total number of liquid/very soft stools for the 7 days prior to the Week 52 visit being ≤ 10 (from CDAI Item 1); and (2) an abdominal pain (graded from 0 [less severe]-3 [more severe]) rating of ≤ 1 (from CDAI Item 2) on each day for the 7 days prior to the Week 52 visit. CDAI score is a weighted, composite index of 8 items (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extraintestinal manifestations including fistula, use or non-use of antidiarrheal agents, presence or absence of abdominal mass, hematocrit, and body weight). Scores range from 0 to approximately 600 with higher scores indicating greater disease severity. (NCT02240108)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg6
Placebo1

[back to top]

Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1 and 2 Both) Over Time

Clinical Symptom Remission defined by (1) the total number of liquid/very soft stools for the 7 days prior to each clinical visit being ≤ 10 (from CDAI Item 1); and (2) an abdominal pain (graded from 0 [less severe]-3 [more severe]) rating of ≤ 1 (from CDAI Item 2) on each day for the last 7 days prior to each clinic visit in ≥ 80% of the study visits during the 52-week treatment period, including Week 52. CDAI score is a weighted, composite index of 8 items (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extraintestinal manifestations including fistula, use or non-use of antidiarrheal agents, presence or absence of abdominal mass, hematocrit, and body weight). Scores range from 0 to approximately 600 with higher scores indicating greater disease severity. (NCT02240108)
Timeframe: From Baseline to Week 52

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg2
Placebo3

[back to top]

Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1) at Week 16

Clinical symptom remission defined by (1) the total number of liquid/very soft stools for the 7 days prior to the Week 16 visit being less than or equal to (≤) 10 (from CDAI Item 1). CDAI score is a weighted, composite index of 8 items (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extraintestinal manifestations including fistula, use or non-use of antidiarrheal agents, presence or absence of abdominal mass, hematocrit, and body weight). Scores range from 0 to approximately 600 with higher scores indicating greater disease severity. (NCT02240108)
Timeframe: Week 16

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg6
Placebo8

[back to top]

Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1) at Week 52

Clinical symptom remission defined by (1) the total number of liquid/very soft stools for the 7 days prior to the Week 52 visit being ≤ 10 (from CDAI Item 1). CDAI score is a weighted, composite index of 8 items (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extraintestinal manifestations including fistula, use or non-use of antidiarrheal agents, presence or absence of abdominal mass, hematocrit, and body weight). Scores range from 0 to approximately 600 with higher scores indicating greater disease severity. (NCT02240108)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg7
Placebo3

[back to top]

Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 2) at Week 16

Clinical Symptom Remission defined by (2) an abdominal pain (graded from 0 [less severe]-3 [more severe]) rating of ≤ 1 (from CDAI Item 2) on each day for the 7 days prior to the Week 16 visit. CDAI score is a weighted, composite index of 8 items (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extraintestinal manifestations including fistula, use or non-use of antidiarrheal agents, presence or absence of abdominal mass, hematocrit, and body weight). Scores range from 0 to approximately 600 with higher scores indicating greater disease severity. (NCT02240108)
Timeframe: Week 16

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg19
Placebo15

[back to top]

Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 2) at Week 52

Clinical Symptom Remission defined by (2) an abdominal pain (graded from 0 [less severe]-3 [more severe]) rating of ≤ 1 (from CDAI Item 2) on each day for the 7 days prior to the Week 52 visit. CDAI score is a weighted, composite index of 8 items (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extraintestinal manifestations including fistula, use or non-use of antidiarrheal agents, presence or absence of abdominal mass, hematocrit, and body weight). Scores range from 0 to approximately 600 with higher scores indicating greater disease severity. (NCT02240108)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg9
Placebo5

[back to top]

Number of Participants With Endoscopic Response at Week 52

Endoscopic response defined as a ≥ 3-point decrease in the SES-CD from baseline to the SES-CD score obtained at Week 52. SES-CD is a validated instrument reflecting an endoscopist's global appraisal of mucosal lesions in Crohn's disease. SES-CD grades lesions by location (5 bowel segments: ileum, right colon, transverse colon, left colon, and rectum) using 4 endoscopic variables: ulcer size, extent of ulcerated surface, extent of affected surface, and presence/type of narrowing. The total SES-CD was calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. (NCT02240108)
Timeframe: Baseline, Week 52

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg9
Placebo15

[back to top]

Number of Participants With Endoscopic Response Between Week 16 and 17

Endoscopic response defined as a ≥ 3-point decrease in the SES-CD from baseline to the SES-CD score obtained between Week 16 and Week 17. SES-CD scores were calculated from centrally-read digital video of ileocolonoscopies performed at baseline and between Week 16 and Week 17. SES-CD is a validated instrument reflecting an endoscopist's global appraisal of mucosal lesions in Crohn's disease. SES-CD grades lesions by location (5 bowel segments: ileum, right colon, transverse colon, left colon, and rectum) using 4 endoscopic variables: ulcer size, extent of ulcerated surface, extent of affected surface, and presence/type of narrowing. The total SES-CD was calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. (NCT02240108)
Timeframe: Baseline, Week 16 to 17

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg10
Placebo10

[back to top]

Number of Participants With SES-CD Score of 0 at Week 52

SES-CD is a validated instrument reflecting an endoscopist's global appraisal of mucosal lesions in Crohn's disease. SES-CD grades lesions by location (5 bowel segments: ileum, right colon, transverse colon, left colon, and rectum) using 4 endoscopic variables: ulcer size, extent of ulcerated surface, extent of affected surface, and presence/type of narrowing. The total SES-CD was calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. (NCT02240108)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg0
Placebo3

[back to top]

Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1 and 2 Both) at Week 16

Clinical Symptom Remission defined by (1) the total number of liquid/very soft stools for the 7 days prior to the Week 16 visit being ≤ 10 (from CDAI Item 1); and (2) an abdominal pain (graded from 0 [less severe]-3 [more severe]) rating of ≤ 1 (from CDAI Item 2) on each day for the 7 days prior to the Week 16 visit. CDAI score is a weighted, composite index of 8 items (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extraintestinal manifestations including fistula, use or non-use of antidiarrheal agents, presence or absence of abdominal mass, hematocrit, and body weight). Scores range from 0 to approximately 600 with higher scores indicating greater disease severity. (NCT02240108)
Timeframe: Week 16

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg5
Placebo7

[back to top]

Number of Participants Who Achieved Clinical Remission (Defined as CDAI Score of <150) at Week 16

Clinical remission was defined as a CDAI score of less than 150 points at Week 16. CDAI score is a weighted, composite index of 8 items (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extraintestinal manifestations including fistula, use or non-use of antidiarrheal agents, presence or absence of abdominal mass, hematocrit, and body weight). Scores range from 0 to approximately 600 with higher scores indicating greater disease severity. (NCT02240108)
Timeframe: Week 16

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg17
Placebo12

[back to top]

Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 2) at Week 16

Clinical Symptom Remission defined by (2) an abdominal pain (graded from 0 [less severe]-3 [more severe]) rating of ≤ 1 (from CDAI Item 2) on each day for the 7 days prior to the Week 16 visit. CDAI score is a weighted, composite index of 8 items (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extraintestinal manifestations including fistula, use or non-use of antidiarrheal agents, presence or absence of abdominal mass, hematocrit, and body weight). Scores range from 0 to approximately 600 with higher scores indicating greater disease severity. (NCT02240121)
Timeframe: Week 16

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg18
Placebo20

[back to top]

Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1) at Week 52

Clinical symptom remission defined by (1) the total number of liquid/very soft stools for the 7 days prior to the Week 52 visit being ≤ 10 (from CDAI Item 1). CDAI score is a weighted, composite index of 8 items (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extraintestinal manifestations including fistula, use or non-use of antidiarrheal agents, presence or absence of abdominal mass, hematocrit, and body weight). Scores range from 0 to approximately 600 with higher scores indicating greater disease severity. (NCT02240121)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg8
Placebo5

[back to top]

Number of Participants Who Achieved Clinical Remission (Defined as CDAI Score of <150) at Week 16

Clinical remission was defined as a CDAI score of less than 150 points at Week 16. CDAI score is a weighted, composite index of 8 items (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extraintestinal manifestations including fistula, use or non-use of antidiarrheal agents, presence or absence of abdominal mass, hematocrit, and body weight). Scores range from 0 to approximately 600 with higher scores indicating greater disease severity. (NCT02240121)
Timeframe: Week 16

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg12
Placebo15

[back to top]

Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1) at Week 16

Clinical symptom remission defined by (1) the total number of liquid/very soft stools for the 7 days prior to the Week 16 visit being ≤ 10 (from CDAI Item 1). CDAI score is a weighted, composite index of 8 items (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extraintestinal manifestations including fistula, use or non-use of antidiarrheal agents, presence or absence of abdominal mass, hematocrit, and body weight). Scores range from 0 to approximately 600 with higher scores indicating greater disease severity. (NCT02240121)
Timeframe: Week 16

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg9
Placebo9

[back to top]

Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1 and 2 Both) at Week 16

Clinical Symptom Remission defined by (1) the total number of liquid/very soft stools for the 7 days prior to the Week 16 visit being ≤ 10 (from CDAI Item 1); and (2) an abdominal pain (graded from 0 [less severe]-3 [more severe]) rating of ≤ 1 (from CDAI Item 2) on each day for the 7 days prior to the Week 16 visit. CDAI score is a weighted, composite index of 8 items (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extraintestinal manifestations including fistula, use or non-use of antidiarrheal agents, presence or absence of abdominal mass, hematocrit, and body weight). Scores range from 0 to approximately 600 with higher scores indicating greater disease severity. (NCT02240121)
Timeframe: Week 16

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg6
Placebo6

[back to top]

Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1 and 2 Both) at Week 52

Clinical Symptom Remission defined by (1) the total number of liquid/very soft stools for the 7 days prior to the Week 52 visit being ≤ 10 (from CDAI Item 1); and (2) an abdominal pain (graded from 0 [less severe]-3 [more severe]) rating of ≤ 1 (from CDAI Item 2) on each day for the 7 days prior to the Week 52 visit. CDAI score is a weighted, composite index of 8 items (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extraintestinal manifestations including fistula, use or non-use of antidiarrheal agents, presence or absence of abdominal mass, hematocrit, and body weight). Scores range from 0 to approximately 600 with higher scores indicating greater disease severity. (NCT02240121)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg7
Placebo5

[back to top]

Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 1 and 2 Both) Over Time

Clinical Symptom Remission defined by (1) the total number of liquid/very soft stools for the 7 days prior to each clinical visit being ≤ 10 (from CDAI Item 1); and (2) an abdominal pain (graded from 0 [less severe]-3 [more severe]) rating of ≤ 1 (from CDAI Item 2) on each day for the last 7 days prior to each clinic visit in ≥ 80% of the study visits during the 52-week treatment period, including Week 52. CDAI score is a weighted, composite index of 8 items (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extraintestinal manifestations including fistula, use or non-use of antidiarrheal agents, presence or absence of abdominal mass, hematocrit, and body weight). Scores range from 0 to approximately 600 with higher scores indicating greater disease severity. (NCT02240121)
Timeframe: From Baseline to Week 52

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg2
Placebo0

[back to top]

Number of Participants With SES-CD Score of 0 at Week 52

SES-CD is a validated instrument reflecting an endoscopist's global appraisal of mucosal lesions in Crohn's disease. SES-CD grades lesions by location (5 bowel segments: ileum, right colon, transverse colon, left colon, and rectum) using 4 endoscopic variables: ulcer size, extent of ulcerated surface, extent of affected surface, and presence/type of narrowing. The total SES-CD was calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. (NCT02240121)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg2
Placebo3

[back to top]

Number of Participants With Endoscopic Response Between Week 16 and 17

Endoscopic response defined as a ≥ 3-point decrease in the SES-CD from baseline to the SES-CD score obtained between Week 16 and Week 17. SES-CD scores were calculated from centrally-read digital video of ileocolonoscopies performed at baseline and between Week 16 and Week 17. SES-CD is a validated instrument reflecting an endoscopist's global appraisal of mucosal lesions in Crohn's disease. SES-CD grades lesions by location (5 bowel segments: ileum, right colon, transverse colon, left colon, and rectum) using 4 endoscopic variables: ulcer size, extent of ulcerated surface, extent of affected surface, and presence/type of narrowing. The total SES-CD was calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. (NCT02240121)
Timeframe: Baseline, Week 16 to 17

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg16
Placebo16

[back to top]

Number of Participants With Endoscopic Response at Week 52

Endoscopic response defined as a ≥ 3-point decrease in the SES-CD from baseline to the SES-CD score obtained at Week 52. SES-CD is a validated instrument reflecting an endoscopist's global appraisal of mucosal lesions in Crohn's disease. SES-CD grades lesions by location (5 bowel segments: ileum, right colon, transverse colon, left colon, and rectum) using 4 endoscopic variables: ulcer size, extent of ulcerated surface, extent of affected surface, and presence/type of narrowing. The total SES-CD was calculated as the sum of the 4 variables for the 5 bowel segments: rectum, left colon, transverse colon, right colon, and ileum. Scores range from 0 to 60, with higher scores indicating more severe disease. (NCT02240121)
Timeframe: Baseline, Week 52

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg11
Placebo10

[back to top]

Number of Participants Who Achieved Clinical Symptom Remission (From CDAI Item 2) at Week 52

Clinical Symptom Remission defined by (2) an abdominal pain (graded from 0 [less severe]-3 [more severe]) rating of ≤ 1 (from CDAI Item 2) on each day for the 7 days prior to the Week 52 visit. CDAI score is a weighted, composite index of 8 items (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extraintestinal manifestations including fistula, use or non-use of antidiarrheal agents, presence or absence of abdominal mass, hematocrit, and body weight). Scores range from 0 to approximately 600 with higher scores indicating greater disease severity. (NCT02240121)
Timeframe: Week 52

InterventionParticipants (Count of Participants)
Rifaximin EIR 800 mg16
Placebo13

[back to top]

Campylobacteriosis

"A clinical illness meeting at least one of the following patterns:~Moderate to severe diarrhea.~Fever (present on at least 2 occasions, at least 20 minutes apart) without diarrhea, plus an associated symptom (nausea, vomiting, abdominal cramps, tenesmus, or gross blood in ≥ 2 stools); with consideration of potential alternative diagnosis per clinical investigator based on illness time course and associated symptoms." (NCT02280044)
Timeframe: 120 hours after challenge

InterventionParticipants (Count of Participants)
Rifaximin13
Placebo11

[back to top]

Recrudescent Events

Recovered C jejuni from fecal specimen on follow-up after an apparent cure (NCT02280044)
Timeframe: 84 Days

InterventionParticipants (Count of Participants)
Rifaximin2
Placebo3

[back to top]

Change in Serum Trimethylamine N-oxide (TMAO)

(NCT02342639)
Timeframe: Change from baseline to Day 11

InterventionuM (Mean)
Rifaximin-3.9
Placebo0.5

[back to top]

Change in Serum Interleukin-6 (IL-6)

post- minus pre-treatment values (NCT02342639)
Timeframe: Change from baseline to day 11

Interventionpg/ml (Mean)
Rifaximin0.3
Placebo0.8

[back to top]

C-reactive Protein

(NCT02342639)
Timeframe: Change from baseline to Day 11

Interventionug/ml (Mean)
Rifaximin6.0
Placebo-2.6

[back to top]

Number of Participants Who Achieved Clinical Cure at TOC Visit (Within 24 to 72 Hours From the Time of Last Dose): Modified Intent-to-Treat (mITT) Population

"Clinical cure was defined as either of the following: No stools or only formed stools within a 48-hour period and no fever, with or without other enteric symptoms or; No watery stools or no more than 2 soft stools passed within a 24-hour period with no fever and no other enteric symptoms except for mild excess gas/flatulence. Participants discontinued early for reasons other than lack of treatment effect after completing 9 doses within 72 hours from the time of first dose and for participants whose condition worsened and who required alternate or supplemental therapy for the treatment of travelers' diarrhea were included in the mITT population analysis using LOCF." (NCT02498418)
Timeframe: TOC visit (Day 5, 6 ,or 7)

InterventionParticipants (Count of Participants)
Generic Rifaximin 200 mg Tablets91
Xifaxan 200 mg Tablets95
Rifaximin Placebo Tablets86

[back to top]

Time to Last Unformed Stool (TLUS)

TLUS was defined as the interval beginning with the first dose of study drug and ending with the last unformed stool passed within a period of 120 hours (within 48 hours from the time of last dose [at 72 hours]). Mathematically, TLUS was calculated as follows. TLUS (hours) = date/time of last unformed stool within 48 hours from the time of last dose - date/time of first dose. (NCT02498418)
Timeframe: Day 1 to Day 5

Interventionhours (Median)
Generic Rifaximin 200 mg Tablets65.25
Xifaxan 200 mg Tablets65.75
Rifaximin Placebo Tablets67.01

[back to top]

Percentage of Participants Who Achieved Microbiological Cure at TOC Visit (Within 24 to 72 Hours From the Time of Last Dose)

Participants were considered to have achieved microbiological cure if the pathogen identified at Day 1 is no longer found in the stool at the TOC visit. (NCT02498418)
Timeframe: TOC visit (Day 5, 6, or 7)

,,
Interventionpercentage of participants (Number)
Escherichia coliEnterotoxigenic Escherichia coli (ETEC)Enteroaggregative Escherichia coli (EAEC)Other microorganismsStool microscopy for ova and parasites
Generic Rifaximin 200 mg Tablets25.543.532.070.683.3
Rifaximin Placebo Tablets17.468.426.192.9100.0
Xifaxan 200 mg Tablets31.954.527.381.8100.0

[back to top]

Number of Participants Who Achieved Clinical Cure at Test of Cure (TOC) Visit (Within 24 to 72 Hours From the Time of Last Dose): Per-Protocol (PP) Population

Clinical cure was defined as either of the following: No stools or only formed stools within a 48-hour period and no fever, with or without other enteric symptoms or; No watery stools or no more than 2 soft stools passed within a 24-hour period with no fever and no other enteric symptoms except for mild excess gas/flatulence. Bioequivalence evaluation between test (generic rifaximin 200 mg tablets) and reference groups (xifaxan 200 mg tablets) was conducted in this endpoint, hence placebo group was not included. Participants who were discontinued early from the study due to lack of treatment effect after completing 9 doses within 72 hours from the time of first dose were included in the PP population using Last Observation Carried Forward (LOCF) method. Additionally, participants whose condition worsened and who required alternate or supplemental therapy for the treatment of travelers' diarrhea were discontinued and included in the PP population analysis using LOCF. (NCT02498418)
Timeframe: TOC visit (Day 5, 6 or 7)

InterventionParticipants (Count of Participants)
Generic Rifaximin 200 mg Tablets90
Xifaxan 200 mg Tablets93

[back to top]

Tolerability of Treatment

Patients with side effects present during treatment and in the 4 weeks after end of treatment (NCT03124199)
Timeframe: 1 month

Interventionparticipants (Number)
with diarrheawith metallic tasteheadachenauseaabdominal pain
Rifaximin139551

[back to top]

Percentage of Participants With H.Pylori Infection Eradication

Percentage of Participants with H.Pylori Infection Eradication confirmed with urea breath test at least 4 weeks after the end of treatment (NCT03124199)
Timeframe: 1 month

Interventionpercentage of participants (Number)
Rifaximin61

[back to top]

Compliance With Treatment of Patients That Completed the Study

Percentage of patients that has comply with treatment, considered as intake of more than 90% of study drugs in patients who attended the post-treatment visit. (NCT03124199)
Timeframe: 1 month

Interventionpercentage of participants (Number)
Rifaximin100

[back to top]

Association of Urgency Symptom and Rectal Sensitivity Testing.

Association of urgency symptom and rectal sensitivity will be evaluated by the mean change in the balloon pressure (measured in mmHg) that leads to first urge sensation to defecate, evaluated based on the visual analogue scale defined in the primary outcome measure. (NCT03462966)
Timeframe: After completing 14-day course of rifaximin.

InterventionMillimetre of mercury (Mean)
Therapeutic106

[back to top]

Mean Change in the Balloon Volume (Measured in Cubic Centimeter) That Leads to First Urge to Defecate.

A 100-cubic centimeter visual analogue scale with verbal descriptors (0=no sensation, 20=first sensation, 40=first sense of urge, 60=normal urge to defecate, 80=severe urge to defecate, and 100=discomfort/pain) will be used to score evoked sensations. (NCT03462966)
Timeframe: After completing 14-day course of rifaximin.

Interventionvolume cubic centimeter (Mean)
Therapeutic37.5

[back to top]

Number of Participants With a Rise of Hydrogen <20 Parts Per Million Within 90 Minutes of Lactulose Ingestion.(Which is Considered Normal )

"Normalization of lactulose breath test as a potential predictor of improvement of rectal hypersensitivity will be evaluated by comparing lactulose breath test results pre- and post-treatment.~Normalization of lactulose breath test defined as rise of hydrogen <20 Parts per million within 90 minutes of lactulose ingestion.~patients with positive" (NCT03462966)
Timeframe: After completing 14-day course of rifaximin

InterventionParticipants (Count of Participants)
Therapeutic2

[back to top]

Time to Overt Hepatic Encephalopathy (OHE) Resolution Determined Using the Hepatic Encephalopathy Grading Instrument (HEGI), Defined as HEGI Score < 2

A participant was considered to have an overt HE episode if at least one of the following applied: (1) Disorientated to time or place or person, (2) Lethargic and has asterixis, (3) Inability to assess the patient due to disorientation to time and place and person; and/or somnolence, and/or coma. Severity of OHE episodes was graded using the HEGI scale, where Grade 1 is no clinical findings of OHE, and Grade 4 is comatose. Higher scores on the scale have higher severity (worse outcome). (NCT03515044)
Timeframe: 14 days

Interventionhours (Median)
Cohort 1 40 mg Rifaximin SSD Once Daily36.1
Cohort 2 40 mg Rifaximin SSD Twice Daily21.1
Cohort 3 80 mg Rifaximin SSD Once Daily45.9
Cohort 4 80 mg Rifaximin SSD Twice Daiy17.9
Cohort 5 Placebo Twice Daily62.7

[back to top]

Time to Hospital Discharge

Time in days until discharge from the hospital (NCT03515044)
Timeframe: 14 days

Interventiondays (Median)
Cohort 1 40 mg Rifaximin SSD Once Daily3.0
Cohort 2 40 mg Rifaximin SSD Twice Daily3.0
Cohort 3 80 mg Rifaximin SSD Once Daily3.0
Cohort 4 80 mg Rifaximin SSD Twice Daiy4.0
Cohort 5 Placebo Twice Daily4.5

[back to top]

Time to Improvement in Hepatic Encephalopathy Grading Instrument (HEGI) Score, Defined as at Least One Grade Decrease (Improvement)

A participant was considered to have an overt HE episode if at least one of the following applied: (1) Disorientated to time or place or person, (2) Lethargic and has asterixis, (3) Inability to assess the patient due to disorientation to time and place and person; and/or somnolence, and/or coma. Severity of OHE episodes was graded using the HEGI scale, where Grade 1 is no clinical findings of OHE, and Grade 4 is comatose. Higher scores on the scale have higher severity (worse outcome). (NCT03515044)
Timeframe: 14 days

Interventiondays (Median)
Cohort 1 40 mg Rifaximin SSD Once Daily2.5
Cohort 2 40 mg Rifaximin SSD Twice Daily2.0
Cohort 3 80 mg Rifaximin SSD Once Daily2.0
Cohort 4 80 mg Rifaximin SSD Twice Daiy2.0
Cohort 5 Placebo Twice Daily3.0

[back to top]

Number of Participants With Adverse Events by the End of the Trial

End of trial is defined as 7 (+/-3) days after last study treatment (NCT03712280)
Timeframe: within 15 days

,,,
InterventionParticipants (Count of Participants)
Affected by Serious Adverse EventsAffected by Any Non-serious Adverse EventAffected by Non-serious Adverse Events in the 5% Reporting Threshold
Group A: MNK6106 2 Grams (Tid)055
Group B: MNK6106 4 Grams (Bid)066
Group C: MNK6106 4 Grams (Tid)298
Group D: Rifaximin 550 mg (Bid)055

[back to top]

Ammonia Plasma Levels at Baseline and Day 5

"This test measures the level of ammonia in your blood. Ammonia, also known as NH3, is a waste product made by your body during the digestion of protein. Normally, ammonia is processed in the liver, where it is changed into another waste product called urea. Urea is passed from the body in urine.~If your body cannot process or eliminate ammonia, a lab test of a blood sample shows it has built up in the bloodstream. High ammonia levels in the blood can lead to serious health problems, including hepatic encephalopathy." (NCT03712280)
Timeframe: Baseline, Day 5

,,,
Interventionμmol/L (Mean)
BaselineDay 5/Pre-Dose in the MorningDay 5/4 Hours Post Morning Dose
Group A: MNK6106 2 Grams (Tid)70.472.769.8
Group B: MNK6106 4 Grams (Bid)91.463.960.9
Group C: MNK6106 4 Grams (Tid)92.674.973.0
Group D: Rifaximin 550 mg (Bid)78.175.871.6

[back to top]

Time of the Maximum Concentration (Tmax)

Time of the maximum concentration (Tmax) of rifaximin and 25-desacetyl rifaximin, if measurable (NCT03818672)
Timeframe: 7 days

Interventionhours (Mean)
rifaximin25-desacetyl rifaximin
Rifaximin0.6880.625

[back to top]

Area Under the Plasma Concentration Versus Time Curve (AUC) During the 12-hour Dose Interval

Area under the plasma concentration versus time curve (AUC) during the 12-hour dose interval of rifaximin and 25-desacetyl rifaximin, if measurable (NCT03818672)
Timeframe: 7 days

Interventionh*ng/mL (Geometric Mean)
rifaximin25-desacetyl rifaximin
Rifaximin98.73.04

[back to top]

Maximum Observed Plasma Concentration (Cmax)

Maximum observed plasma concentration (Cmax) of rifaximin and 25-desacetyl rifaximin, if measurable (NCT03818672)
Timeframe: 7 days

Interventionng/mL (Geometric Mean)
rifaximin25-desacetyl rifaximin
Rifaximin13.40.356

[back to top]

Change in Interleukin 4 (IL-4)

Change in Interleukin 4 after Rifaximin (NCT03856359)
Timeframe: Baseline, 3 months

Interventionpg/mL (Mean)
Rifaximin-17.40

[back to top]

Change in Interleukin 2 (IL-2)

Change in Interleukin 2 following Rifaximin (NCT03856359)
Timeframe: Baseline, 3 months

Interventionpg/mL (Mean)
Rifaximin-0.33

[back to top]

Change in Cognitive Performance on the Mini-Mental State Exam (MMSE)

Change from baseline global cognitive scores at month 3). Global cognitive performance will be assessed by a psychometrician using the (MMSE). It is a brief cognitive questionnaire with a maximum score of 30 points. MMSE range is 0-30 with lower scores indicating worse performance. The number of correct answers is added to generate the total score. (NCT03856359)
Timeframe: Baseline, 3 months

Interventionscore on a scale (Mean)
Rifaximin-0.3

[back to top]

Change in Glial Fibrillary Acidic Protein (GFAP)

Change in Glial Fibrillary Acidic Protein (GFAP) after 3 months of oral Rifaximin (NCT03856359)
Timeframe: Baseline, 3 months

Interventionpg/mL (Mean)
Rifaximin-39.76

[back to top]

Participants With Treatment Emergent Adverse Events as Reported by the Subject That Required a Change in Safety Measures

Emergent AEs that required a change in safety measures. These were AEs that were found when talking to or examining the subjects. (NCT03856359)
Timeframe: Safety will be measured through adverse events throughout study, at month 3 and by phone call at month 5 (2 months after treatment termination).

Interventionpercentage of participants (Number)
Rifaximin0

[back to top]

Change in ADAS Cog 11 Scores

Change in Alzheimer's Disease Assessment Scale - Cognition test with 11 tasks (ADAS Cog 11) scores following 3 months of oral Rifaximin. Scores range from minimum 0 - maximum 70. Higher scores mean worse outcome. (NCT03856359)
Timeframe: At baseline and at 3 months

Interventionscore on a scale (Mean)
Rifaximin30.5

[back to top]

Change in Interleukin 10 (IL-10)

Change in Interleukin 10 following 3 months Rifaximin (NCT03856359)
Timeframe: Baseline, 3 months

Interventionpg/mL (Mean)
Rifaximin00.70

[back to top]

Total Tau

Change in serum Total tau after 3 months Rifaximin administration. (NCT03856359)
Timeframe: Baseline, 3 months

Interventionng/mL (Number)
Rifaximin-0.17

[back to top]

Phosphorylated Tau

Change in Phosphorylated tau following 3 months oral Rifaximin (NCT03856359)
Timeframe: at baseline and at 3 months

Interventionng/mL (Mean)
Rifaximin-0.39

[back to top]

Number of Participants Experiencing Diarrhea Caused by Clostridium Difficile

Collected at every visit and follow-up phone visits. A rare side effect of Rifaximin is diarrhea caused by clostridium difficile. This is a very serious form of diarrhea that can be fatal if not treated. The investigators will be following the patients closely during treatment and for 2 months following treatment to see if the patient has any signs or symptoms of this diarrhea. If a patient does develop clostridium difficile diarrhea, they will be promptly treated. (NCT03856359)
Timeframe: 5 months

InterventionParticipants (Count of Participants)
Rifaximin5

[back to top]

Development of Clostridium Difficile Diarrhea

Observing for development of diarrhea due to Clostridium difficile (NCT03856359)
Timeframe: Baseline to 3 months

Interventionpercentage of subjects (Number)
Rifaximin0

[back to top]

Changes in Interleukin 13 (IL-13) Following Treatment With Rifaximin

Interleukin 13 levels after Rifaximin (NCT03856359)
Timeframe: Baseline, 3 months

Interventionpg/mL (Mean)
Rifaximin-1.78

[back to top]

Change in Interleukin 5 (IL-5)

Change in Interleukin 5 after Rifaximin (NCT03856359)
Timeframe: Baseline, 3 months

Interventionpg/mL (Mean)
Rifaximin-0.87

[back to top]

Change in Tumor Necrosis Factor a

Change in Tumor Necrosis Factor a (NCT03856359)
Timeframe: Baseline, 3 months

Interventionpg/mL (Mean)
Rifaximin-0.46

[back to top]

Change in Tolerability as Measured by Number of Adverse Events (AE).

Assessed at every visit. The patients will be followed closely to see if they are tolerating the drug, Rifaximin. The of the number of side effects would indicate that the patient may not be tolerating the drug. Most of these side effects are minor and include headache, nausea, vomiting, tiredness. A potentially fatal side effect would be the development of clostridium difficile diarrhea. The investigators will be following the patients closely during treatment and for 2 months following treatment to see if the patient has any signs or symptoms of this diarrhea. If a patient does develop clostridium difficile diarrhea, they will be promptly treated. (NCT03856359)
Timeframe: Baseline, 3 months, 5 months

InterventionParticipants (Count of Participants)
Rifaximin7

[back to top]

Change in Neurofilament Light (Nfl) Levels

Change in Neurofilament Light levels after Rifaximin for 3 months (NCT03856359)
Timeframe: Baseline, 3 months

Interventionng/L (Mean)
Rifaximin-4.22

[back to top]

Change in Interleukin 8 (IL-8)

Change in Interleukin 8 after Rifaximin (NCT03856359)
Timeframe: Baseline, 3 months

Interventionpg/mL (Mean)
Rifaximin-1.31

[back to top]

Change in Interleukin 6 (IL-6)

Change in Interleukin 6 following Rifaximin (NCT03856359)
Timeframe: Baseline, 3 months

Interventionpg/mL (Mean)
Rifaximin-1.62

[back to top]

Change in Interleukin 1B (IL-1B)

Change in Interleukin 1B following Rifaximin (NCT03856359)
Timeframe: Baseline, 3 months

Interventionpg/mL (Mean)
Rifaximin-0.1

[back to top]

Changes From Baseline in Ammonia Level

Change in ammonia levels following treatment with Rifaximin. (NCT03856359)
Timeframe: Baseline, 3 months

Interventionmg/dL (Mean)
Rifaximin0.1

[back to top]

Change in Stool Frequency

"Change in stool frequency from baseline, as determined from diary data comparing Rifaximin alone vs Rifaximin and NAC~determined from daily stool diary data~The change in bowel movements/day between two time points is reported baseline and 4 weeks after cessation of treatment (at 6 weeks)" (NCT04557215)
Timeframe: value at 6 weeks minus value at baseline

Interventionnumber of bowel movements (Mean)
Rifaximin 550 mg-0.04
Rifaximin 200 mg + Placebo-0.50
Rifaximin 200 mg Plus N-acetylcysteine (NAC) 600 mg Days-0.24

[back to top]

Change in Stool Form

"Change in stool form from baseline, as determined from stool diary data comparing Rifaximin alone vs rifaximin and NAC~The Bristol Stool Chart, the minimum value is 1 (means constipation) and maximum value is 7 (means diarrhea).~The change between two time points is reported baseline and 4 weeks after cessation of treatment (at 6 weeks)" (NCT04557215)
Timeframe: value at 6 weeks minus value at baseline

Interventionscore on a scale (Mean)
Rifaximin 550 mg-0.26
Rifaximin 200 mg + Placebo-0.45
Rifaximin 200 mg Plus N-acetylcysteine (NAC) 600 mg Days-0.49

[back to top]

Change in Abdominal Pain

"Change in severity of abdominal pain from baseline, as determined from weekly average visual analog scale (VAS) scores, relative to Rifaximin alone. VAS scores allows subject to choose 0 for no pain to 100 pain as bad as it could possibly be.~The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 no pain and 100 pain as bad as it could possibly be~The change between two time points is reported baseline and 4 weeks after cessation of treatment (at 6 weeks)" (NCT04557215)
Timeframe: value at 6 weeks minus value at baseline

Interventionunits on a scale (Mean)
Rifaximin 550 mg-5.43
Rifaximin 200 mg + Placebo-8.90
Rifaximin 200 mg Plus N-acetylcysteine (NAC) 600 mg Days-5.59

[back to top]